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Abstract 
Tissue engineering is a highly promising technology for the treatment of challenging 
cartilage and bone lesions for which no adequate therapeutic options are available 
yet. However for their widespread use, engineered tissues will first have to prove a 
predictable clinical success. To reach this objective, a reproducibly high product 
quality will be required, which can be achieved by a better knowledge and a 
continuous control of the cell phenotype during all phases of the tissue engineering 
process. The aim of this thesis is therefore to demonstrate how two types of 
mesenchymal cells, chondrocytes and bone marrow-derived mesenchymal/stromal 
cells (BMSC), can be modulated during growth and differentiation in order to 
conserve and fully exploit their potential. The present work is divided into 4 chapters. 
Chapter I will reveal how different chondrocyte subpopulations change their 
phenotype during in vitro proliferation and how this can lead to the detection of cells 
with increased differentiation capacity. In chapter II, the parameters governing the 
maintenance of osteogenic potential of BMSC during expansion will be analyzed. 
Chapter III will demonstrate how the coculture of BMSC with macrophages can result 
in a better cartilage-forming capacity. Finally in chapter IV, the effect of ascorbic acid 
on chondrogenic differentiation will be established. 
Chapter I: The De-differentiation of Human Chondrocytes is Linked to 
Individual Cell Divisions 
The relationship between proliferation and de-differentiation of chondrocytes during 
in vitro culture remains poorly understood. It was hypothesized here that cell 
proliferation tracking could reveal differences in the progression of de-differentiation 
and chondrogenic potential among subpopulations proliferating at different rates. 
Results showed that changes in the expression of cell surface markers and 
extracellular matrix genes were linked to individual cell divisions. Different culture 
conditions influenced cell doubling rates but not the relationship between cell 
divisions and phenotypic alterations, which indicated a strong coupling between both 
phenomena. Interestingly the highest chondrogenic potential was measured for 
slowly growing chondrocytes, even after a same number of total doublings was 
reached for all subpopulations. The increased understanding of the link between 
proliferation, de-differentiation and re-differentiation capacity will lead to innovative 
ways to maintain chondrogenic differentiation potential during chondrocyte 
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expansion. It will also facilitate the identification of progenitor populations with 
intrinsically superior capacity for the generation of enhanced engineered cartilage 
grafts. 
Chapter II: Perfused 3D Scaffolds and Hydroxyapatite Substrate Maintain the 
Osteogenic Potential of Human Bone Marrow-Derived Mesenchymal Stromal 
Cells during Expansion 
In previous studies it was repeatedly shown that the expansion of bone marrow-
derived mesenchymal/stromal cells (BMSC) on 3D ceramic scaffolds resulted in 
increased maintenance of osteogenic potential as compared to culture on 2D 
polystyrene (PS). Since several culture parameters completely differ between 3D 
ceramic and 2D PS culture, the individual influences of the 3D scaffold and the 
ceramic material, as well as of the extracellular matrix deposition were investigated 
here. Results revealed that BMSC expanded on 2D PS only yielded bone matrix if 
the culture time was not longer than 2 weeks. Cells cultured for 3 weeks on both 3D 
PS and 3D ceramic scaffolds produced a dense bone matrix. The number of explants 
containing bone was higher with cells expanded on 3D ceramic compared to 3D PS. 
However there were no significant differences between cells extracted from 3D 
ceramic and directly implanted constructs. These findings suggest that the bone-
forming capacity of BMSC can be maintained by a 3D environment and further 
improved by a ceramic substrate material, but that a preexisting 3D niche is not 
required for bone formation. The preservation of BMSC with osteogenic potential 
during 3D expansion in bioreactors opens the perspective for a streamlined 
production of large-scale bone grafts for clinical use. 
Chapter III: Anti-Inflammatory/Tissue Repair Macrophages Enhance the 
Cartilage-Forming Capacity of Human Bone Marrow-Derived Mesenchymal 
Stromal Cells 
Macrophages play a key role in healing processes, by regulating inflammation and 
stimulating tissue repair. However their influence on the tissue formation potential of 
BMSC is unknown. The effect of the coculture of macrophages with either pro-
inflammatory or tissue-remodeling traits on the chondrogenic differentiation capacity 
of BMSC was therefore tested here. Results showed that the coculture of BMSC with 
tissue-repair but not with pro-inflammatory macrophages resulted in significantly 
higher glycosaminoglycan content and type II collagen expression, while type X 
collagen expression was unaffected. This chondro-inductive effect was found to be 
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caused by an increased survival and higher clonogenic and chondrogenic capacity of 
BMSC that were cocultured with tissue-repair macrophages. No difference was 
detected however in the cartilage tissue maturation in nude mice, as evidenced by 
similar accumulation of type X collagen and calcified tissue. These results 
demonstrated that a coculture with tissue-repair macrophages can improve the 
chondrogenic differentiation capacity of BMSC. This increased knowledge can lead to 
new coculture strategies for the manufacturing of cartilage grafts with enhanced 
quality. 
Chapter IV: Chondrogenic Differentiation and Collagen Synthesis of Human 
Chondrocytes in the Absence of Ascorbic Acid 
Ascorbic acid is considered to be an important supplement for cartilage tissue 
engineering because of its role in collagen hydroxylation in vivo. Due to its instability, 
ascorbic acid requires specific liquid handling conditions, which poses significant 
challenges to the automation of cartilage graft manufacturing. The aim of this study 
was to investigate the effect of ascorbic acid on chondrogenesis in vitro, with special 
regard to collagen synthesis and hydroxylation. Results showed that cartilage gene 
expression, tissue formation, and production of glycosaminoglycans were 
indistinguishable whether chondrocyte micromass pellets were cultured with or 
without ascorbic acid. Not adding ascorbic acid caused a reduction of collagen 
deposition, but collagen hydroxylation was not significantly different. Collagen 
secretion was unaffected and collagens showed a similar fibril structure in the 
absence of ascorbic acid. In conclusion, ascorbic acid did not influence 
chondrogenesis except for a small effect on collagen quantity, and can thus be 
omitted to simplify automation for a more cost-efficient cartilage graft manufacturing. 
Conclusion 
In this work, four different approaches to modulate the growth and differentiation of 
chondrocytes and BMSC were presented. With the gained knowledge the cell 
phenotype can be better controlled during manufacturing processes, which will be 
required for the production of engineered tissue grafts with reproducibly high quality 
for clinical translation. 
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General Introduction 
In this first section, the main topics covered by my thesis will be introduced. An 
overview of articular cartilage and bone tissue composition and biology will be given, 
which will be completed with a summary of therapeutic options for common cartilage 
and bone lesions. Next, I will explain how the emerging field of tissue engineering 
can deal with current limitations in tissue regeneration. I will particularly enlarge upon 
current approaches in cartilage and bone tissue engineering, highlight the remaining 
challenges and indicate which role bioreactors could play for the widespread clinical 
use of engineered tissue grafts. In the thesis outline, I will state the specific aims and 
scientific questions answered by my thesis. The following chapters will then 
demonstrate how the mentioned challenges in cartilage and bone tissue engineering 
can be overcome by the modulation of growth and differentiation of mesenchymal 
cells. I will finish with a general conclusion and future perspectives. 
A. Articular cartilage 
1. Structure and properties 
Articular cartilage is the connective tissue layer that covers the surface of synovial 
joints. This tissue has unique biomechanical features, providing at the same time 
resilience to compression, dampening of loads, and lubrication of the gliding surface. 
The unmatched properties of articular cartilage emanate from its highly organized 
structural and molecular composition and are essential for stable movement with low 
friction (Fig. 1) (Buckwalter and Mankin, 1998a). Only a few millimeters in thickness, 
articular cartilage contains a low density of a single cell type, the chondrocyte, but 
neither blood vessels, nor lymphatic vessels, nor nerves. During development, 
articular cartilage arises from a dense population of mesenchymal cells in the 
cartilage anlage that are expressing specific transcription factors and signaling 
molecules at the prospective joint site and differentiate into articular chondrocytes 
(Decker et al., 2014). The chondrocytes are embedded in small cavities called 
lacunae, which offer protection, and are specialized in synthesizing a dense 
extracellular matrix (ECM) that consists mainly of collagen proteins, proteoglycans, 
and interstitial fluid (Mow et al., 1992). The principal collagen of articular cartilage is 
collagen type II which is structured in a fibrillary meshwork and gives the tensile 
strength. Whereas collagens type IX and type XI are thought to further stabilize the 
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collagen network, collagen type IV surrounds and shelters the chondrocytes in the 
lacunae. Aggrecan as the core protein and the attached glycosaminoglycans such as 
chondroitin sulfate and keratin sulfate constitute most proteoglycans. The 
proteoglycans themselves are bound via link protein to a hyaluronan backbone; 
hence articular cartilage is also referred to as hyaline cartilage. The aqueous 
interstitial fluid contains a high concentration of cations to counterbalance the 
negatively charged proteoglycans, which together contribute to the tissue stiffness 
through the occurrence of swelling pressures (Buckwalter and Mankin, 1998a). 
Articular cartilage is arranged into different zones according to the depth from the 
joint surface. The superficial zone consists of a thin sheet of densely packed collagen 
fibrils oriented parallel to the surface and flattened chondrocytes secreting lubricin 
and other anti-adhesive factors to ensure friction-less movement. The chondrocytes 
in the middle/transitional zone are round and produce randomly arranged ECM fibers 
that contribute to the resilience of cartilage. In the deep/radial zone chondrocytes and 
fibers are aligned perpendicular to the surface. This cartilage layer is adjacent to the 
tide mark, which serves as a boundary to the deeper subchondral bone (Decker et 
al., 2014). The cartilage ECM is slowly but continuously remodeled throughout 
lifetime to maintain its composition, organization, and functionality, however 
alterations may appear with age and injury (Buckwalter and Mankin, 1998b). 
 
Figure 1: The structural and molecular composition of articular cartilage at different scales (illustration 
reprinted from Biomaterials 13, 67–97. Mow, V. C., Ratcliffe, A. and Poole, A. R. Cartilage and 
diarthrodial joints as paradigms for hierarchical materials and structures, copyright 1992, with 
permission from Elsevier). 
 13 
 
2. Cartilage lesions and treatments 
Cartilage lesions mainly result from trauma or a progressive degeneration with age 
known as osteoarthritis (OA). Since cartilage is avascular and chondrocytes have a 
low metabolism, self-repair of damaged cartilage is very limited. After a mechanical 
insult or age-related deterioration, the ECM structure and chondrocyte activity further 
decline over time, finally leading to a loss of joint function, associated with strong pain 
(Buckwalter and Mankin, 1998b; Gelber, 2000). To treat damaged articular cartilage, 
a wide range of surgical procedures has been developed. For end-stage OA, total 
knee arthroplasty, during which the entire joint is replaced by an artificial prosthesis, 
is the most common treatment. However due to the limited durability of these 
synthetic devices and the complications associated with revision surgery, this 
technique is only suitable for elderly patients. An alternative treatment for localized 
cartilage defects in the younger population is a technique called microfracture which 
consists of drilling holes into the underlying subchondral bone to stimulate the 
regeneration by resident progenitor cells from the marrow. Another surgical method 
named mosaicplasty comprises the transplantation of pieces of healthy cartilage from 
non-weight bearing regions to the defect area. However the disadvantage of this 
procedure is the resulting donor site morbidity (Bhosale and Richardson, 2008). 
Autologous chondrocyte implantation (ACI) and the more recent matrix-assisted ACI 
(MACI) are two cell-based techniques that consist of an in vitro expansion of isolated 
autologous chondrocytes and their reinjection in the defect site as a suspension or in 
combination with a supportive matrix (Bartlett et al., 2005; Brittberg et al., 1994). The 
clinical outcome of the above techniques is highly variable because the newly 
generated tissue is mostly fibrocartilage with biomechanical properties that are 
inferior to those of native articular cartilage (Bhosale and Richardson, 2008). The 
clinical need for cartilage repair thus persists and requires innovative treatments with 
better long-term outcomes. The emerging field of tissue engineering could remedy to 
this problem by providing mechanically functional grafts of hyaline cartilage tissue 
made from autologous cells. 
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B. Bone  
1. Structure and properties 
Bone, the principal component of the skeleton, is a vascularized connective tissue 
that provides structural stability, enables mobility and protects the organs of the 
human body. Moreover bone is a site of hematopoiesis and serves as a calcium and 
phosphate reservoir. Bone is composed of different cell types and has an 
extracellular matrix made of an organic part, mainly collagen, and an inorganic 
mineralized component. Bone formation occurs during development by either of two 
distinct processes: intramembranous ossification or endochondral ossification. The 
bones of the skull are formed by intramembranous ossification when mesenchymal 
cells condensate and differentiate directly into osteoblasts. The osteoblasts secrete 
an extracellular matrix rich in collagen type I and generate thereby the so-called 
osteoid that starts to be calcified by the deposition of minerals. The osteoblasts in the 
osteoid become osteocytes and produce the spongy/trabecular bone tissue around 
emerging blood vessels. The osteoblasts on the outside of the osteoid give rise to the 
periosteum which forms a surrounding solid layer of compact/cortical bone (Gilbert, 
2000). During endochondral ossification, which is the process by which the other 
bones of the body are created, condensed mesenchymal cells first differentiate into 
chondrocytes and produce a cartilaginous template. The chondrocytes become 
hypertrophic and attract blood vessels, while the matrix starts to be mineralized. The 
hypertrophic chondrocytes subsequently undergo apoptosis. The surrounding cells of 
the perichondrium differentiate into osteoblasts and produce the compact bone collar. 
Osteoblasts invading with the blood vessels generate the primary ossification center 
of spongy bone, where also the bone marrow develops. At the end of the bones, a 
secondary ossification center forms by the same process of chondrocyte hypertrophy 
and osteoblast invasion. During childhood bones are further growing in length due to 
proliferating and differentiating chondrocytes in the growth plate adjacent to this 
secondary ossification center (Fig. 2) (Kronenberg, 2003). Throughout life bone 
undergoes a constant process of remodeling during which, in a very coordinated 
manner, old bone is resorbed by osteoclasts that have differentiated from monocytes 
and new bone is produced by osteoblasts. This whole process is thought to be 
orchestrated by mechanosensing osteocytes (Raggatt and Partridge, 2010). 
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Figure 2: Steps of endochondral ossification. a. Condensation of mesenchymal cells. b. Differentiation 
into chondrocytes (c). c. Chondrocytes become hypertrophic (h). d. Hypertrophic chondrocytes 
produce mineralized extracellular matrix, attract blood vessels, and undergo apoptosis. Surrounding 
cells of the perichondrium become osteoblasts and form the bone collar (bc). e. Osteoblasts invading 
with the blood vessels generate the primary ossification center of spongy bone (ps). f. and g. The 
secondary ossification center (soc) forms at the end of the bones. Bones are further growing in length 
due to proliferating and differentiating chondrocytes (col). The bone marrow (hm) develops in the 
spongy bone (illustration reprinted by permission from Macmillan Publishers Ltd: Nature, 423, 332–
336. Kronenberg, H. M. Developmental regulation of the growth plate, copyright 2003). 
2. Bone lesions and treatments 
Fractures are the most common bone lesions and heal under normal circumstances 
in an efficient physiological process. Bone fracture healing occurs by either of two 
distinct processes, which resemble developmental bone formation: primary or 
secondary healing. The majority of fractures heal via secondary healing, an indirect 
process that resembles the route of endochondral ossification, involving the formation 
of a cartilaginous soft callus by invading mesenchymal progenitor cells, which is then 
mineralized and remodeled by osteoclasts and osteoblasts (Schindeler et al., 2008). 
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Very stable fractures restore through primary fracture healing, which proceeds by 
resorption of bone fragments by osteoclasts and deposition of new bone by 
osteoblasts (Sfeir et al., 2005). To improve bone fracture healing, partial stabilization 
by internal or external fixation can be applied to unite the fracture (Perren, 2002). 
However, bone regeneration can be severely impaired by several factors, as in the 
case of large segmental defects, absence of vascularization, and osteoporotic or 
inflammatory environments, which need additional treatment. More advanced 
therapies are also applied in other conditions that require the formation of new bone 
such as spinal fusion, maxillary sinus elevation, or craniofacial reconstruction due to 
congenital defects or after tumor excision. In these challenging cases, therapeutic 
options include autografts with substitute material harvested from the patient’s iliac 
crest, allografts of demineralized bone, and synthetic biomaterials. Additionally 
autologous bone marrow or growth factors such as bone morphogenetic proteins 
(BMP) can be administered. Although these treatments can provide good clinical 
outcomes, several shortcomings such as insufficient osteogenesis, donor site 
morbidity, or therapeutic side-effects have been reported (De Long et al., 2007; 
Dimitriou et al., 2011). Bone tissue engineering offers the possibility to overcome 
these current issues by generating large functional bone grafts that closely mimic the 
physiological bone formation process and support the body’s self-healing capacity 
(Amini et al., 2012). 
C. Tissue Engineering 
The aim of tissue engineering is to generate functional biological grafts in order to 
repair damaged tissues, improve organ functions or regenerate entire body parts. 
These artificial living substitutes are generated from cells cultured in vitro on a 
supportive material and being instructed with specific physico-chemical signals. To 
achieve these complex interactions between human cells, materials, and molecules, 
an interdisciplinary approach combining methods and principles of engineering, 
medical, and life sciences is required (Langer and Vacanti, 1993; Lanza et al., 2011). 
In the standard tissue engineering paradigm, a tissue biopsy is harvested, from which 
cells are isolated and expanded in vitro in 2D dishes. When a sufficient number of 
cells have been reached, the cell suspension is seeded on a scaffold material. Most 
commonly porous materials – a plethora of different biomaterials and architectures 
exist – or hydrogels are used as scaffolds. The role of the scaffold on the one hand is 
to give the necessary structural support to the cells and to the produced ECM. On the 
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other hand the scaffold provides further biomechanical and biochemical signals that 
instruct the cells to differentiate and produce the wanted distinctive ECM (Chen et al., 
1997; Engler et al., 2006). After the construct culture phase that allows the tissue to 
mature, the generated graft is then transplanted into the patient (Fig. 3). Besides 
being used in therapeutic applications, tissue engineered constructs can also serve 
as in vitro model systems to study tissue development and disease, or to perform 
drug testing under more physiological conditions (Hirt et al., 2014; Martin et al., 
2004). 
 
Figure 3: The standard tissue engineering paradigm. Cells are isolated from a tissue biopsy and 
expanded in 2D. Expanded cells are seeded on a 3D scaffold material and instructed to secrete the 
specific extracellular matrix. The mature tissue graft is then implanted into the patient. 
1. Cartilage tissue engineering 
Since cartilage consists of only one cell type and is avascular, the production of 
newly engineered cartilage grafts seems straightforward. Still the neocartilage needs 
to perfectly mimic the complex and unique properties of native cartilage, i.e. 
withstand considerable external forces and at the same time allow a smooth 
movement of the joints. The successful treatment of cartilage lesions by joint 
resurfacing with engineered cartilage still has to be verified in clinical trials involving 
large patient numbers. However, a better long-term outcome is generally expected 
when the cells accumulate high amounts of collagen type II and aggrecan, because 
these grafts have better biomechanical properties (Vunjak-Novakovic et al., 1999). In 
Patient
Scaffold
Cell isolation Cell expansion
Construct cultureTissue graft
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order to produce cartilage in vitro, typically autologous chondrocytes are harvested 
from a non-weight-bearing region of the joint. Alternatively, chondrocytes can be 
obtained from the nasal septum, the ribs or the ear. From all these tissues, only low 
cell numbers can be isolated, due to the limited size of biopsies. The different 
chondrocyte sources have advantages and disadvantages related to their 
accessibility and donor site morbidity on the one hand, and the biological 
performance of the cells on the other hand (Candrian et al., 2008; Kafienah et al., 
2002; Pelttari et al., 2014; Scotti et al., 2011; Tay et al., 2004). More engineered 
extracellular matrix (ECM) can be achieved from higher cell densities, but increased 
cell numbers are only beneficial if the cells still have the capacity to produce the right 
protein composition (Francioli et al., 2010; Moretti et al., 2005; Woods et al., 2007). In 
fact, in contrast to terminally differentiated chondrocytes that almost never divide in 
vivo, isolated chondrocytes quickly proliferate in vitro, but also start altering their 
gene expression, from mainly collagen type II and aggrecan to mostly collagen type I 
and versican (Benya and Shaffer, 1982; Binette et al., 1998). This process is called 
de-differentiation and progresses with cell passages. Since de-differentiation is only 
partially reversible, overly expanded chondrocytes have lost their potential to produce 
a hyaline-like cartilaginous matrix (Giovannini et al., 2010; Schulze-Tanzil et al., 
2004). The fibrous matrix that de-differentiated chondrocytes produce instead has 
poor biomechanical properties and cannot be used anymore for tissue engineering 
applications. In order to better maintain the chondrogenic potential during 
proliferation and to increase the deposition of extracellular matrix when cells are 
supposed to re-differentiate, different growth factor cocktails are commonly added 
(Jakob et al., 2001; Yaeger et al., 1997). Nevertheless current engineered cartilage 
tissues still lack the reproducibly high quality required for a broader use in the clinic, 
partially due to the insufficient knowledge and control over the chondrocyte 
phenotype during proliferation and differentiation processes. Moreover, chondrocytes 
are known to have a substantial intra- and inter-donor variability (Barbero et al., 2003; 
Barbero et al., 2004). Different approaches have been proposed to identify 
chondrocytes with an increased intrinsic chondrogenic potential (Candela et al., 
2014; Dowthwaite et al., 2004; Grogan et al., 2007; Pretzel et al., 2011; Williams et 
al., 2010). However, a defined set of distinctive markers to prospectively isolate and 
better characterize these cell populations is still missing. 
Mesenchymal stem/stromal cells derived from the bone marrow (BMSC) or other 
tissues, as well as induced pluripotent stem cells (iPSC) have been proposed as 
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alternative cell sources for cartilage tissue engineering. All these cell types 
theoretically have the capacity to differentiate into chondrocytes. However their 
potential can be variable, leading to an unpredictable composition of extracellular 
matrix that is unsuitable for engineered cartilage grafts. Moreover, to date, 
phenotypic stability of these cells can still not be completely ensured. This can result 
in unwanted side-effects such as the further differentiation of BMSC into hypertrophic 
chondrocytes, which will cause the cartilaginous extracellular matrix to turn into bone 
in a process similar to endochondral ossification (Bhattacharjee et al., 2015; Centola 
et al., 2013; Craft et al., 2015; Diekman et al., 2012; Hellingman et al., 2012). 
Innovative approaches are therefore required to increase the cartilage-forming 
capacity of BMSC and to possibly stabilize their phenotype for use in cartilage tissue 
engineering applications. 
2. Bone tissue engineering 
Engineered bone grafts could become an attractive therapeutic alternative 
considering the limitations of current clinical treatments of bone lesions. However for 
an adequate repair, bone grafts need not only to have the right biomechanical 
features, but also to allow for a fast integration into the surrounding bone tissue and 
vasculature. Ideally, tissue engineered bone should thus have high osteoinductive 
and angiogenic potential and it should be available in different sizes, of-the-shelf and 
at reasonable cost (Amini et al., 2012). Similar to its developmental formation, bone 
can be engineered via direct osteogenesis, a process resembling intramembranous 
ossification, or via a hypertrophic cartilage template which is inspired by 
endochondral ossification. Besides giving rise to a functional bone marrow, the latter 
procedure is also considered to be biologically more reproducible (Scotti et al., 2010; 
Scotti et al., 2013). Amongst others, mesenchymal stem/stromal cells from bone 
marrow (BMSC), adipose tissue and other sources, or iPSC can be used to generate 
bone (Szpalski et al., 2012). The advantage of certain cell sources is that through 
their chondrogenic potential, it is easier to induce them to an endochondral 
ossification process. On the other hand, cell sources containing progenitors for blood 
vessels, such as the stromal vascular fraction of fat tissue, can help in ensuring a fast 
vascularization of engineered bone grafts (Güven et al., 2011). BMSC can be 
harvested from bone marrow aspirates, however they account for less than 0.01% of 
the total number of isolated cells and therefore need an enormous amount of cell 
doublings before the required number of cells for a tissue engineering application is 
reached (Pittenger et al., 1999). The differentiation potential of BMSC decreases with 
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increasing passages in monolayer culture, probably due to a number of factors that 
are inherently different to their native environment. (Banfi et al., 2000; Hoch and 
Leach, 2014). In case BMSC cannot differentiate anymore into to osteoblasts or 
chondrocytes, they produce a fibrous matrix that is not osteoinductive and will not 
turn into bone upon implantation, resulting into poor bone healing and graft failure. A 
number of protocols have been developed to better preserve the BMSC 
differentiation potential for bone tissue engineering, such as the expansion in 
bioreactors on ceramic scaffolds (Braccini et al., 2005; Papadimitropoulos et al., 
2014). Nevertheless, further research efforts are required to better understand and 
also learn how to control the phenotype of BMSC in order to exploit their full potency 
for the clinical translation of engineered bone grafts. 
3. Bioreactors for tissue engineering 
Bioreactors are systems that allow carrying out biological processes under defined 
and controlled conditions. By ensuring a closed environment with stable temperature, 
pH, and gas supply and by providing a constant provision of nutrients and removal of 
waste products, bioreactors can help in tissue engineering applications to increase 
process and product standardization, safety and quality. Bioreactors also offer the 
possibility for automation and scale-up, which can further improve reproducibility and 
cost-effectiveness. Moreover bioreactors cannot only be used to generate 
engineered tissues, but also as 3D culture model systems mimicking aspects of the 
in vivo environment (Martin et al., 2004; Martin et al., 2009; Martin et al., 2014; Wendt 
et al., 2009). Mechanical bioreactors are used for example to provide physical stimuli 
in order to activate mechanobiological cell pathways or to test the performance of the 
engineered constructs (Démarteau et al., 2003; Grad et al., 2011). Since manual 
procedures of cell seeding usually result in irregular cell patterns and poor cell 
penetration, bioreactor systems have been designed to ensure the perfusion of the 
3D scaffold for homogeneous cell and tissue distribution (Wendt et al., 2003; Wendt 
et al., 2006). The advantage of higher mass transfer rates of such a perfusion culture 
also enables the generation of large cartilage grafts (Santoro et al., 2010). From a 
regulatory perspective, bioreactors allow a simple integration of in-process controls 
(Santoro et al., 2011). Merging these engineering principles, tissue engineering 
production processes can be streamlined by combining cell expansion and the 
following graft maturation in perfusion bioreactors, eliminating the need for numerous 
costly and labor-intensive manual steps (Fig. 4) (Wendt et al., 2011). 
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Figure 4: In the streamlined tissue engineering paradigm, the cell seeding, cell expansion and 
construct maturation phases are performed consecutively in the same perfused 3D bioreactor. In this 
way, several costly and labor-intensive manual steps can be eliminated. 
In this way the use of bioreactors could, together with the mentioned increased 
reproducibility and quality, be key for the widespread clinical translation of tissue 
engineered products (Wendt et al., 2009). In order to also achieve a fully automated 
workflow, the time-consuming exchange of culture medium can be replaced in 
bioreactors with a completely automated system (Asnaghi et al., 2009). However, 
complex process requirements such as the handling of many different liquids often 
hinder the automation of tissue manufacturing. Before being implemented in 
bioreactors, the frequently inefficient manual processes thus need to be reconsidered 
and simplified by applying novel concepts originating from new insights in cell 
biology.  
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Thesis Outline 
Aim 
Despite many advances in the field of cartilage and bone tissue engineering during 
the last years, translation to the clinic could be observed only in some cases (Fulco et 
al., 2014; Liebergall et al., 2013; Pelttari et al., 2014; Saris et al., 2008). Current 
problems include low standardization and high manufacturing costs (Martin et al., 
2014), but also a lack of reproducibility due to incomplete control over the cell 
behavior, leading to an insufficient tissue maturation and quality in vitro with 
unpredictable clinical outcome. For a widespread use of engineered tissues in the 
treatment of cartilage and bone lesions, a better knowledge and ideally a continuous 
control of the cell phenotype during all phases of the tissue engineering process are 
therefore essential. The aim of this thesis is to demonstrate how the phenotype of 
two types of mesenchymal cells, chondrocytes and bone marrow derived 
mesenchymal/stromal cells (BMSC), can be modulated during growth and 
differentiation to conserve and fully exploit their potential (Fig. 5). 
Since tissue engineering is highly multidisciplinary, all the studies presented here 
were done in collaboration with other researchers. The individual contributions are 
highlighted on the first page of each chapter. 
Chapter I: The De-differentiation of Human Chondrocytes is Linked to 
Individual Cell Divisions 
During in vitro expansion, the phenotype of articular chondrocytes quickly changes 
and their chondrogenic potential is progressively lost. However the interrelation 
between chondrocyte proliferation and concurrent de-differentiation remains poorly 
understood. In order to investigate how phenotypic changes relate to cell divisions 
and to study how this possible link is influenced by different culture environments, cell 
division tracking of freshly isolated chondrocytes was performed. It was hypothesized 
that selecting chondrocytes based on their number of cell divisions reveals 
differences among subpopulations in the progression of de-differentiation and in their 
chondrogenic potential. With an improved understanding of the interplay between 
chondrocyte proliferation and de-differentiation, innovative ways of cell expansion 
and/or selection can be developed that preserve the full chondrogenic potential for 
the manufacturing of enhanced cartilage grafts. 
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Chapter II: Perfused 3D Scaffolds and Hydroxyapatite Substrate Maintain the 
Osteogenic Potential of Human Bone Marrow-Derived Mesenchymal Stromal 
Cells during Expansion 
The expansion of BMSC on perfused 3D ceramic scaffolds leads to more extensive 
and more reproducible in vivo bone formation than BMSC cultured in monolayer on 
2D polystyrene (PS). Given that the bioreactor-based culture of BMSC on 3D ceramic 
inherently encompasses several aspects that are completely different than in 2D PS 
and could substantially affect the in vivo osteogenic potential, the aim of this work 
was to investigate the individual roles of i) the 3D scaffold vs 2D surface and of ii) the 
ceramic vs PS substrate material during expansion, as well as of iii) the extracellular 
matrix deposited before implantation. An enhanced control over the culture 
parameters responsible for the preservation of the osteogenic capacity of BMSC 
during expansion will allow the further use of these cells in clinical applications. 
Chapter III: Anti-Inflammatory/Tissue Repair Macrophages Enhance the 
Cartilage-Forming Capacity of Human Bone Marrow-Derived Mesenchymal 
Stromal Cells 
Macrophages exerting different functions have been identified as key players in 
healing processes due to their capacity to secrete growth factors and cytokines 
(Brown et al., 2014; Park and Barbul, 2004). However the direct influence of 
macrophages on the tissue forming capacity of BMSC is unknown. The aim of this 
study was therefore to investigate whether macrophages with pro-inflammatory or 
tissue-remodeling traits could modulate the chondrogenic differentiation of BMSC in 
vitro and if this would have consequences for the cartilage tissue maturation in vivo. 
Moreover, the cellular mechanisms possibly accounting for this phenomenon were 
assessed. An increased understanding of their interactions with BMSC can help in 
developing strategies to selectively recruit and polarize macrophages for improved 
chondrogenic differentiation or phenotypic stabilization. 
Chapter IV: Chondrogenic Differentiation and Collagen Synthesis of Human 
Chondrocytes in the Absence of Ascorbic Acid 
The introduction of automation for the manufacturing of engineered cartilage is 
essential for a broad clinical adoption in the long-term, but unstable medium 
supplements pose significant challenges to automation due to their special 
requirements for liquid handling. Ascorbic acid is such an unstable compound that is 
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added to chondrogenic medium because of its role in collagen hydroxylation. The aim 
of this part of the work was to investigate the effect of ascorbic acid on the 
chondrogenesis of human nasal chondrocytes, with special regard to collagen 
synthesis and hydroxylation. The knowledge of the precise requirements for ascorbic 
acid during chondrogenic differentiation will help to develop appropriate automation 
strategies that ensure the manufacturing of high quality engineered cartilage grafts. 
 
 
 
Figure 5: Outline of the scientific questions addressed in this thesis. Chondrocytes will be selected 
based on their number of cell divisions to assess differences among subpopulations in the progression 
of phenotypic changes and in their chondrogenic potential (Chapter I). In the streamlined tissue 
engineering paradigm, the influence of the 3D scaffold, the scaffold material and the matrix formation 
on the osteogenic potential of BMSC will be investigated (Chapter II). The effect of tissue-repair and 
pro-inflammatory macrophages on the chondrogenic capacity of BMSC will be tested (Chapter III). 
The influence of ascorbic acid on the chondrogenesis of chondrocytes will be studied, with special 
regard to collagen synthesis and hydroxylation (Chapter IV). 
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ABSTRACT 
The production of engineered cartilage using primary chondrocytes typically requires 
an initial in vitro expansion phase, during which cells lose their native phenotype and 
chondrogenic potential. The relationship between chondrocyte proliferation and de-
differentiation remains however poorly understood. We hypothesized that cell 
proliferation tracking reveals differences in the progression of de-differentiation and 
chondrogenic potential among subpopulations. Following the doublings of freshly 
isolated human chondrocytes allowed the distinction of cells dividing at 
heterogeneous rates during culture. Changes in the expression of cell surface 
markers CD54, CD90 and CD166 as well as of extracellular matrix genes collagen 
type I, collagen type II, aggrecan and versican were linked to individual cell divisions. 
Different culture conditions influenced cell doubling rates but not the relation to 
phenotypic alterations indicating a strong coupling between both phenomena. 
Interestingly the highest chondrogenic potential was measured for slowly growing 
chondrocytes, even after a same number of total doublings was reached. This 
increased understanding of the interrelation between proliferation, de-differentiation 
and re-differentiation capacity will help in finding innovative ways to maintain 
chondrogenic differentiation potential during chondrocyte expansion and in identifying 
progenitor populations with intrinsically superior capacity for the generation of 
enhanced engineered cartilage grafts. 
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INTRODUCTION 
Biological joint resurfacing with grafts engineered from autologous chondrocytes has 
been reported to hold great promise for the treatment of damaged articular cartilage 
(Pelttari et al., 2014; Santoro et al., 2010). In order to obtain a sufficient number of 
cells for the production of these large-size grafts, considerable cell expansion from a 
small cartilage biopsy is required. During the expansion phase chondrocytes start to 
de-differentiate by changing the expression of characteristic genes and cell surface 
markers (Benya and Shaffer, 1982; Binette et al., 1998; Diaz-Romero et al., 2005). 
Since de-differentiation is only partially reversible, chondrogenic potential is 
progressively lost with cell proliferation and overly expanded chondrocytes hardly 
produce any hyaline cartilage matrix (Schulze-Tanzil, 2009). The onset of 
proliferation and de-differentiation of terminally differentiated chondrocytes in culture 
is presumably caused by the imposed culture environment. The provision of 3D 
environments, matched substrate stiffness, extracellular matrix components or 
growth factors have thus been proposed to better maintain the chondrocyte 
phenotype during proliferation (Barbero et al., 2006; Jakob et al., 2001; Mhanna et 
al., 2014; Schrobback et al., 2011; Schuh et al., 2010). Nevertheless these methods 
only delay the decline of cartilage formation capacity and the connection between 
proliferation and concurrent de-differentiation of articular chondrocytes in in vitro 
culture remains poorly understood. 
The progressive phenotypic changes and loss of chondrogenic differentiation 
potential with cell passages and cumulative population doublings suggests that 
proliferation and de-differentiation are coupled (Giovannini et al., 2010; Schulze-
Tanzil et al., 2004). However the assessment of cell populations after expansion 
rather than single cells results in an averaging of possible subsets, dominated by 
rapidly dividing cells and masking slower growing subpopulations. For chondrocytes 
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this could be particularly of an issue since clonal studies have shown that primary 
cells from a same cartilage biopsy proliferate with very heterogeneous growth 
kinetics and have variable re-differentiation potential (Barbero et al., 2003; Barbero et 
al., 2005). 
The fluorescent proliferation tracking dye carboxyfluorescein succinimidyl ester 
(CFSE) has been widely used in vitro and in vivo to analyze cell populations with 
heterogeneous growth rates such as lymphocytes or hematopoietic stem cells on a 
single cell level (Parish, 1999; Takizawa and Manz, 2012). When CFSE-labeled cells 
divide, their fluorescence is halved among the two daughter cells, which allows the 
determination of the number of prior divisions of each individual cell over multiple 
generations. From the fluorescence profiles, proliferation kinetics in response to 
extracellular signals and the link between phenotypical changes and cell divisions 
can then be established (Hasbold et al., 1999; Hawkins et al., 2007). 
Proliferation tracking of freshly isolated chondrocytes was performed here to 
investigate the connection between single cell divisions and phenotypic changes and 
to study how this possible link is influenced by different culture environments. We 
hypothesized that selecting chondrocytes based on their number of cell divisions 
reveals differences among subpopulations in the progression of de-differentiation and 
in their chondrogenic potential. With an improved understanding of the interplay 
between chondrocyte proliferation and de-differentiation, innovative ways of cell 
expansion and/or selection can be developed that preserve the full chondrogenic 
potential for the manufacturing of enhanced cartilage grafts. 
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MATERIALS AND METHODS 
Cell isolation and CFSE labeling 
Full-thickness samples of human articular cartilage were collected from the tibial 
plateaus of 2 cadavers and 9 patients undergoing total knee replacement (mean age 
68 years, range 56 – 84 years) after informed consent by relatives or patients 
respectively and in accordance to the local ethical commissions (University Hospital 
Basel). Only the macroscopically healthy cartilage parts were considered for this 
study. Cells were isolated during 22 h at 37°C using 0.15% collagenase II 
(Worthington, USA), as previously described (Jakob et al., 2003). After digestion, 
cells were resuspended at a concentration of 1x106 cells/ml in phosphate buffered 
saline (PBS; Gibco, Life Technologies, Switzerland). Carboxyfluorescein diacetate 
succinimidyl ester (Sigma, Switzerland) diluted in PBS was immediately added to the 
cell suspension at a final concentration of 1 µM to yield the fluorescent intracellular 
division tracking dye carboxyfluorescein succinimidyl ester (CFSE). After 5 minutes 
of incubation in the dark at room temperature, the reaction was quenched by addition 
of a large excess of cold complete medium (CM) consisting of Dulbecco's modified 
Eagle's medium containing 4.5 mg/ml D-glucose and 0.1 mM nonessential amino 
acids, supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 100 mM 
HEPES buffer, 100 U/ml penicillin, 100 μg/ml streptomycin, and 0.29 mg/ml L-
glutamine (all from Life Technologies). Since CFSE staining of chondrocytes lead to 
a wide distribution of initial fluorescence (Chawla et al., 2010), where indicated, cells 
were sorted 24 h after labeling using a FACSAria III cell sorter (BD Biosciences, 
USA) to obtain a lower coefficient of variation of fluorescence. These chondrocytes 
with a narrow CFSE fluorescence distribution were used to generate visually 
distinctive peaks of generations of proliferating cells (Nordon et al., 1999). 
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Cell culture 
Cells were plated in tissue culture flasks at a density of 1x104 cells/cm2 and cultured 
in CM with or without (no GF) growth factors consisting of 1 ng/ml transforming 
growth factor beta 1 and 5 ng/ml fibroblast growth factor 2 (both from R&D Systems, 
UK) at 37°C and 5% CO2 in a humidified incubator (Heraeus, Thermo Scientific, 
USA) with medium exchange every 3 days (Barbero et al., 2005). A control of 
undivided CFSE labeled cells was generated by addition of colchicine (Sigma) at a 
concentration of 100 ng/ml. To inhibit Rho small GTPases, a modified C3 transferase 
(CT04, Cytoskeleton, USA) was added at a final concentration of 0.5 µg/ml. Cell 
culture in tissue culture flasks was monitored on an IX50 inverted microscope with 
phase contrast (Olympus, Japan). At the indicated time points, cells were detached 
using 0.05% trypsin-EDTA (Gibco) and further processed. In case of re-plating after 
FACS sorting, cells were seeded at a density of 5x103 cells/cm2 and grown in CM 
with growth factors until reaching 90% confluence.  
Flow cytometry and fluorescence-activated cell sorting 
The expression of cell surface markers was measured by staining chondrocytes with 
saturating concentrations of mouse antibodies conjugated to phycoerythrin (PE) or 
allophycocyanin (APC) against human CD49c, CD54, CD90 and CD166 (all from BD 
Biosciences) diluted in PBS supplemented with 0.1% bovine serum albumin and 2 
mM EDTA (both from Sigma). Matched isotype controls (BD Biosciences) were used 
to set negative gates. A final concentration of 2 µg/ml of 4',6-diamidino-2-
phenylindole (DAPI; Sigma) was added shortly before analysis to gate out dead cells. 
Flow cytometric measurements of CFSE and stained cell surface markers were 
performed on an LSRFortessa (BD Biosciences). Data were analyzed using FlowJo 
v10.0.7 (Tree Star Inc., USA) and modeled by series of equally spaced Gaussian 
curves cells with ModFit LT v4 (Verity Software House, USA) to determine the 
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number of cells in each generation, using the peak position and standard deviation of 
CFSE-labeled colchicine-treated (Hawkins et al., 2007). From the number of cells in 
each generation i, precursor numbers were calculated as  
𝑝𝑟𝑒𝑐𝑢𝑟𝑠𝑜𝑟 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑖𝑜𝑛 𝑖 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑖𝑜𝑛 𝑖 2𝑖−1⁄  
Precursor frequencies were then determined by dividing for each generation the 
calculated precursor number by the sum of precursors from all generations (Nordon 
et al., 1999). Additionally, chondrocytes were sorted after 6 days of proliferation into 
4 groups according to their number of cell divisions derived from their retention of 
CFSE-associated fluorescence, to be assessed by RT-PCR, chondrogenically re-
differentiated in micromass pellets, or further expanded. 
Quantitative RT-PCR 
mRNA of chondrocytes was extracted using Quick-RNA Miniprep (Zymo Research, 
Germany), according to the manufacturer’s protocol. DNaseI (Zymo Research) was 
used to remove trace DNA. Isolated RNA was quantified using a NanoDrop 
spectrophotometer (Thermo Fischer Scientific, USA). Reverse transcription into 
cDNA was done from 3 μg of RNA by using 500 μg/ml random hexamers (Promega, 
USA) and 0.5 μl of 200 UI/ml SuperScript III reverse transcriptase (Invitrogen), in the 
presence of dNTPs. Quantitative real-time PCR was carried out on an ABI Prism 
7700 Sequence Detection System (Perkin-Elmer/Applied Biosystems, Switzerland). 
After an initial denaturation at 95°C for 10 min, cDNA was amplified for 40 cycles, 
each consisting of a denaturation step at 95°C for 15 s and an annealing/extension 
step at 60°C for 60 s. Primers and probes for aggrecan, versican, collagen type I, 
collagen type II and GAPDH were used as previously described (Martin et al., 2001). 
Assay on-Demand (Applied Biosystems) was used to measure the expression of 
SOX9 (Hs00165814_m1). For each sample, the threshold cycle (Ct) value of the 
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reference gene GAPDH was subtracted from the Ct value of the gene of interest, to 
derive ΔCt. The relative gene expression of each group normalized to the unsorted 
whole cell population was calculated as 2-ΔΔCt. Each sample was assessed at least in 
duplicate for each gene of interest. 
Bioreactors and alginate encapsulation 
For culture in perfusion bioreactors, 5x104 freshly isolated CFSE-stained 
chondrocytes were seeded on Hyalofast scaffolds (6 mm diameter, 2 mm thick; Anika 
Therapeutics, Italy) coated with 50 µg/ml fibronectin (Sigma). A superficial velocity of 
1 mm/s was applied for 16 h, then cells were cultured for 6 additional days at a 
superficial velocity of 100 mm/s in CM with growth factors and medium exchange 
after 3 days (Santoro et al., 2011). 
Alternatively 5x104 labeled chondrocytes were re-suspended in 1 ml of 1.25% 
alginate solution (Sigma) and encapsulated in 102 mM CaCl2 (Sigma) solution as 
previously described (De Ceuninck et al., 2004). Beads were cultured for 7 days in 
CM with growth factors, with medium exchange after 3 days, and afterwards 
dissolved using 50 mM EDTA. 
Chondrogenic differentiation 
Chondrocytes were re-differentiated as spherical pellets of 1x105 cells/well, formed 
by centrifugation at 300xg in 96-well plates with V-shaped bottom (Sarstedt, 
Germany), in serum-free D-MEM medium (Gibco) containing 1 mM sodium pyruvate, 
100 mM HEPES buffer, 100 U/ml penicillin, 100 μg/ml streptomycin, and 0.29 mg/ml 
L-glutamine, ITS+1 (10 µg/ml insulin, 5.5 µg/ml transferrin, 5 ng/ml selenium, 0.5 
mg/ml bovine serum albumin, 4.7 µg/ml linoleic acid; Sigma, Switzerland), 100 µM 
ascorbic acid 2-phosphate, 1.25 mg/ml human serum albumin, 100 nM 
dexamethasone (Sigma), and 10 ng/ml TGF-β1 (R&D Systems), with medium 
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changed twice weekly. After 3 weeks of culture, pellets were processed 
biochemically for glycosaminoglycan (GAG) and DNA content and histologically for 
Safranin-O staining. 
Biochemical and histological analyses 
Cartilaginous pellets were digested in 250 µl of proteinase K solution containing 1 
mg/ml proteinase K in 50 mM Tris with 1 mM EDTA, 1 mM iodoacetamide, and 10 
mg/ml pepstatin A (all from Sigma) for 16 h at 56°C. The glycosaminoglycan content 
of pellets was determined by spectrophotometry using dimethylmethylene blue, with 
chondroitin sulphate as a standard (Barbosa et al., 2003). The DNA content of pellets 
was measured using the CyQuant cell proliferation assay kit (Invitrogen), with calf 
thymus DNA as a standard. The amount of GAG in pellets was then normalized to 
the DNA content (Barbero, 2004). 
For histology, micromass pellets were fixed overnight in 4% formalin, encapsulated in 
HistoGel (Thermo Scientific) and embedded in paraffin. 5 µm thick sections were 
stained with Safranin-O (Barbero, 2004). 
Statistical analysis 
Data are presented as mean and standard deviation of the indicated number of 
independent experiments. Statistical analysis was performed using two-tailed 
unpaired t-test or one-way ANOVA followed by Tukey’s post hoc test for multiple 
comparisons with Prism software (GraphPad Software, USA). Values of p < 0.05 
were considered statistically significant.  
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RESULTS 
Division tracking reveals differentially proliferating chondrocyte 
subpopulations 
We labeled articular chondrocytes immediately after isolation with the cell 
proliferation tracking dye CFSE in order to identify possible subpopulations based on 
differential growth rates. Analysis of chondrocytes with narrow fluorescence 
distribution revealed distinct peaks of cell divisions after 4 days in culture whereas 
colchicine treated cells did not divide and were concentrated in one single peak of 
uniformly high fluorescence, marking the undivided population (Fig. 1A). The 
modeling of growth kinetics with the help of fluorescence data allowed the attribution 
of generation numbers to the peaks, the quantification of subpopulations and the 
calculation of the frequency of precursor cells. In the proliferating population, the 
fraction of cells that had undergone 0 or 1 division was drastically decreased 
compared to the percentage of their corresponding precursors in the original 
population. Meanwhile the subpopulations with 3 or more divisions had increased 
relatively to the fraction of their precursors (Fig. 1B). Chondrocytes that were not 
sorted for a low coefficient of variation of initial fluorescence showed broad CFSE 
distributions after several days in culture and cells with 6 or more divisions 
approached autofluorescence. Even if no visually distinctive peaks could be 
observed, CFSE profiles of these cells could be still be modeled with Gaussian 
curves showing an overlap between neighboring subpopulations (Fig. 1C). 
 44 
 
 
Figure 1: CFSE staining reveals subpopulations of chondrocytes proliferating at different rates. 
(A) Fluorescence profile measured by flow cytometry of CFSE-stained freshly isolated chondrocytes, 
initially sorted for uniform fluorescence, after 4 days in culture. Proliferation was inhibited with 
colchicine to determine the position of the peak of undivided cells and the coefficient of variation for 
modeling. Numbers of cell divisions are indicated. (B) From the fluorescence profile, the 
subpopulations of different chondrocyte generations were quantified, which then allowed the 
calculation of precursor frequencies in the original population, indicating a rapid overgrowth by faster 
proliferating cells. (C) Fluorescence profile of CFSE-labeled chondrocytes with broad distribution of 
initial fluorescence. Subpopulations were identified based a model (black lines) using equally spaced 
Gaussian curves, showing good fit of the fluorescence measurements (grey line) and partial 
overlapping between successive groups. Cell division numbers (above) and groups of cell divisions for 
cell sorting (below) are indicated. (D) CFSE staining did not influence overall growth rates of 
chondrocytes after 7 and 14 days (n=3 preparations from 1 donor, no statistical difference). (E) 
Surface marker expression, exemplarily shown here for CD90 on day 1 and day 7, was 
B
D
GF
E
subpopulations on day 4
cell divisions
fraction
measured
calculated
precursors
0 4.43% 16.02%
1 16.96% 30.67%
2 41.76% 37.76%
3 31.88% 14.41%
4 4.97% 1.12%
day 1 day 7
 unstained
 undivided
 CFSE
A
C
0
1
2
3
4
5
6+
6+
3-66+ 1-3 0-1
groups of cell divisions
for cell sorting
Modeling of cell divisions
 45 
 
indistinguishable between CFSE-stained and unstained cells. (F) Micromass pellets generated from 
unstained and CFSE treated chondrocytes showed similar Safranin-O staining. Scale bar: 100 µm. (G) 
CFSE staining did not influence GAG/DNA ratios of chondrogenic pellets (n=3 preparations from 1 
donor, no statistical difference). 
To assess potential effects of CFSE staining on cell functions, we assessed the 
growth, de-differentiation, and re-differentiation of CFSE-labeled and unstained cells. 
Results showed that labeled and unstained chondrocyte populations had identic 
overall growth rates (Fig. 1D) and exhibited the same changes in cell surface marker 
expression pattern, exemplarily shown here for CD90 at different time points (Fig. 
1E). Moreover the re-differentiation potential of CFSE-labeled and unstained cells in 
chondrogenic pellet cultures was similar as revealed by Safranin-O staining of 
histological sections and GAG/DNA ratios (Fig. 1F,G). 
Surface marker and gene expression changes are linked to cell divisions 
The changes in expression of the cell surface markers CD54, CD49c, CD90 and 
CD166, all known to indicate the progressive de-differentiation of chondrocytes 
(Diaz-Romero et al., 2005), were measured in combination with CFSE staining to see 
whether there is a connection between phenotypic alterations and individual cells 
divisions. Overall CD166 expression was low in freshly isolated chondrocytes, but 
quickly increased from day 0 to day 7 of in vitro culture (Fig. 2A). When relating 
CD166 expression to cell divisions on day 7, we found that positivity for this marker 
was increasing with the number of individual cell doublings (Fig. 2B). Whereas 
undivided cells stayed mostly CD166-, a significantly higher percentage of cells with 
6 or more divisions were CD166+ (Fig. 2C). CD54 expression decreased with culture 
time (Fig. 2D) and also with cell divisions (Fig. 2E). In contrast to slowly dividing cells 
that retained CD54 expression, almost all rapidly dividing cells were CD54- on day 7, 
indicating a negative correlation between CD54 and cell divisions (Fig. 2F). 
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Figure 2: Changes in cell surface marker expression are linked to cell divisions. Chondrocytes 
were assessed for expression of cell surface markers CD49c, CD54, CD90 and CD166 by flow 
cytometry. (A,D,G,J) Surface marker expression measured on days 0 and 7, confirming changes 
during culture. Gates indicate positive and negative cell fraction on day 7. (B,E,H,K) CFSE and 
surface marker expression on day 7, revealing changes of expression with increasing number of cell 
divisions, except for CD49c. (C,F,I,L) Fraction of cells that for the indicated number of divisions was 
positive for surface marker expression, which confirmed a link between cell doublings and phenotypic 
changes (n=4 donors, * significantly different from 0 cell divisions). (M) CFSE and CD90 expression on 
days 3, 5 and 6, shows progressive CD90 acquisition and proliferation of only CD90+ cells. 
cell divisions
6+ 5 4 3 2 1 0A B C
D E F
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Primary chondrocytes quickly became positive for CD49c (Fig. 2G), but the number 
of CD49c+ cells was high and similar across all numbers of cell doublings, indicating 
an independence of CD49c expression from cell divisions (Fig. 2H,I). The expression 
of CD90 completely shifted from day 0, when the vast majority of cells were negative, 
to day 7 with almost only positive cells (Fig. 2J). Only some of the very slowly 
dividing or non-dividing chondrocytes remained CD90-, but all moderately to fast 
dividing cells were CD90+ (Fig. 2K,L). Interestingly and in contrast to the gradual 
increase of CD166 with cell divisions, when relating CD90 expression to cell 
doublings, two populations separating over time could be distinguished. During the 
first days, cultured primary chondrocytes shifted from CD90- to CD90+ and only 
CD90+ cells started to proliferate, as indicated by diminishing CFSE staining solely in 
this population. As a result the proportion of non-proliferating CD90- chondrocytes 
quickly decreased (Fig. 2M). 
We next measured the expression of cartilage specific genes in relation to cell 
divisions, by sorting chondrocytes after 6 days of culture into 4 different groups. 
Groups were defined according to the number of cells divisions calculated from the 
remaining CFSE fluorescence, taking into account a partial overlapping of 
subpopulations (Fig. 1C, 3A). Whereas the expression of collagen type I increased 
with cell divisions, collagen type II continuously decreased with individual doublings. 
Hence the ratio of collagen type II to collagen type I was negatively correlated with 
cell divisions, leading to a more than 400-fold difference between the slowest and the 
fastest dividing cells after only 7 days (Fig. 3B). A similar result was seen for the ratio 
of aggrecan to versican which also decreased with cell doublings, indicating that 
within a pool of cells de-differentiation was fastest progressing in cells that had 
divided more often (Fig. 3C). Moreover the cartilage transcription factor SOX9 was 
slightly higher expressed in chondrocytes that were dividing slower (Fig. 3D). For all 
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genes measured, the whole population showed an expression that was an average 
of the different groups. 
 
Figure 3: Alteration of expression of cartilage-specific genes progresses with cell divisions. (A) 
Distribution of chondrocytes sorted into each of the 4 groups according to the number of prior cell 
divisions after 6 days of culture. (B) Fold change of gene expression ratio of collagen type II to 
collagen type I, relative to the whole population. The ratio strongly decreases with an increasing 
number of cell divisions. (C) Fold change of gene expression ratio of aggrecan to versican. (D) Fold 
change of gene expression of SOX9 (n=3 donors, * significantly different from whole population). (E, 
F) Gene and surface marker expression of native chondrocytes immediately after isolation and 
chondrocytes that did not divide during culture, suggesting that the culture environment contributes to 
de-differentiation also in the absence of proliferation (n=3 donors, * significantly different from native 
chondrocytes). 
In order to assess how the de-differentiation of chondrocytes was linked to cell 
divisions in relation to other factors, we compared the gene and surface marker 
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expression of cells obtained immediately after isolation and of cells that had 
undergone 0 to 1 divisions during culture (Fig. 3E, F). The expression of all tested 
genes had changed towards de-differentiation also in the absence of proliferation, 
indicating that cell divisions only partially increased the progress of phenotypic 
changes. Interestingly, the changes of the cell surface markers CD90 and CD49c 
seemed to be influenced by the in vitro culture of cells whereas CD54 and CD166 
expression were similar for native and non-dividing cells. 
Coupling of chondrocyte de-differentiation to divisions does not depend on the 
culture environment 
Next we wanted to test whether the observed connection between cell divisions and 
de-differentiation were influenced by the cell culture environment. The use of 3D 
scaffolds in perfused bioreactors and of growth factors permitted to provide different 
growth stimuli. CFSE profiles showed that in the presence of growth factors the 
number of cell divisions in 3D bioreactors was almost identical to those on 2D plastic. 
On the other hand cells grown on 2D dishes without growth factors were dividing 
slower on average, and a smaller percentage of cells from this group had achieved 5 
or more divisions after 7 days (Fig. 4A). The expression of CD49c, CD90 and CD166 
was almost indistinguishable between different culture conditions and followed the 
same trend of progressive change with cell divisions (Fig. 4B,D,E). On the other hand 
the expression of CD54 in 2D was very variable and remained on average higher 
with cell divisions in the absence of growth factors than in their presence (Fig. 4C). 
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Figure 4: Division-linked changes are largely independent of the culture environment. (A) 
Distribution of chondrocyte cell divisions after 7 days of culture on perfused 3D scaffolds or on 2D 
dishes, both with growth factors, or on 2D dishes without growth factors. Similar growth rates were 
found in 3D and 2D with growth factors, but a lower number of doublings occurred in 2D without 
growth factors. (B, C, D, E) Progression of surface marker expression of chondrocytes grown in 3D or 
2D with growth factors, or 2D without growth factors, follows the same trend with cell divisions (n=3 
donors, no statistical differences between groups for the same number of divisions). (F) CFSE and 
CD90 expression on day 7 of chondrocytes cultured on 2D, in alginate beads, or in presence of a Rho 
GTPase inhibitor, all with growth factors, and of native chondrocytes, highlighting that in the absence 
of cell spreading, cells showed very limited proliferation and de-differentiation. 
2D control alginate beads
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To investigate if the cell morphology could affect the relationship between cell 
divisions and phenotypical changes, cells were encapsulated in alginate beads or a 
Rho inhibitor was used to restrict stress fiber formation and cell spreading. In both 
cases, CFSE fluorescence did almost not decrease when compared to the 2D control 
condition, indicating that cells did not or almost not divide. Moreover these cells 
remained mostly CD90- during 7 days, which was in contrast to the CD90+ 
proliferating cells in the control condition. Because the prevention of cell spreading 
inhibited not only cell divisions but also de-differentiation, these results suggested 
that both phenomena were strongly coupled. Moreover the de-differentiation 
progressed slower than for non-dividing cells in the control condition, suggesting that 
cell spreading was a cause of de-differentiation even in the absence of proliferation 
(Fig. 4F). 
Subpopulations of slowly dividing cells maintain a higher chondrogenic 
differentiation potential 
Chondrocytes sorted after 6 days of culture into 4 groups according to their number 
of doublings were re-differentiated as micromass pellets to probe their chondrogenic 
capacity. The best chondrogenesis as assessed by Safranin-O staining and 
GAG/DNA ratio was found for chondrocytes that were growing slowly and had 
undergone 1-3 doublings, whereas the fastest proliferating cells with more than 6 
divisions only produced fibrous tissue and the group containing non-dividing cells did 
not undergo proper pellet formation. The whole population had an intermediate re-
differentiation potential that was significantly lower than the subpopulation with 1-3 
doublings (Fig. 5A,B). 
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Figure 5: The highest chondrogenic differentiation potential is found in slowly dividing cells. (A) 
Representative Safranin-O staining of chondrogenic micromass pellets from cells sorted according to 
their number of divisions or the whole population. Scale bar: 100 µm. (B) Biochemical GAG/DNA 
quantification of chondrogenic pellets, showing the highest ratio for cells that did 1-3 doublings (n=3 
preparations from 1 donor, * significantly different from whole population). 
To test whether the sorted subpopulations had intrinsically different growth kinetics, 
sorted cells were further cultured in monolayer. Results revealed that cells that had 
proliferated fastest during the first 6 days retained the highest doubling rate, 
meanwhile the slowest dividing cells continued to grow with the least population 
doublings per day (Fig. 6A). Moreover 3 days after re-plating, cells displayed different 
morphologies among groups. Cells that had previously undergone 0 to 1 cell division 
had a roundish to polygonal shape, which was in contrast to fast dividing cells 
displaying a spindle-like morphology (Fig. 6C). Cells from all groups were then grown 
until their respective confluence, to assess de-differentiation and chondrogenic 
potential of subpopulations after having reached a similar number of total population 
doublings. The gene expression ratio of collagen type II to collagen type I showed 
that the difference between the fastest and the slowest dividing group was even more 
pronounced, even though in absolute numbers the ratio was lower than after the first 
passage for all groups (Fig. 6B). For one donor these cells were re-differentiated and 
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we found that the chondrocyte subpopulation that was growing slowly, when 
compared to very slowly/non-dividing or rapidly dividing cells, still had the highest 
chondrogenic potential (Fig. 6D). 
 
Figure 6: Differences in growth rate and differentiation potential of subpopulation are 
maintained during additional culture. (A) Population doublings per day of sorted cells that were 
further cultured, indicating that the fastest growing population maintains the highest growth rate (n=3 
preparations from 1 donor, * significantly different from whole population). (B) Fold change of gene 
expression ratio of collagen type II to collagen type I after expansion until a similar number of total 
doublings. The expression is relative to the whole population P1 after 7 days (n=3 preparations from 1 
donor, * significantly different from whole population P2). (C) Phase contrast microscopy of sorted 
populations. Rapidly proliferating cells have a spindle-like morphology, while slowly dividing and non-
dividing cells keep a polygonal to round shape. Scale bar: 100 µm. (D) Safranin-O staining of 
chondrogenic micromass pellets from cells sorted according to their number of divisions or the whole 
population and further expanded until a similar number of total doublings was achieved. Scale bar: 
100 µm. 
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DISCUSSION 
In this study, we investigated cell divisions and concurrent phenotypic changes 
during the in vitro culture of chondrocytes with the help of cell division tracking. 
Results showed that chondrocyte subpopulations could be identified based on 
differential growth rates. When combining cell division tracking with known markers 
of de-differentiation, we found that changes in surface protein and cartilage gene 
expression were linked to the number of cell divisions. The observed partial de-
differentiation of non-dividing cells suggested that phenotypic changes also occurred 
independently of proliferation. Different culture environments influenced growth rates, 
but de-differentiation still progressed with cell divisions. The prevention of cell 
spreading resulted in a drastic decrease of cell growth and de-differentiation, 
indicating a strong coupling between both phenomena. Finally we found that the 
identified chondrocyte subpopulations showed differences in their re-differentiation 
potential, which persisted even when reaching a similar number of cell divisions, 
indicating that slower proliferating subpopulations could be enriched for cells with an 
intrinsically higher chondrogenic capacity. 
We identified chondrocyte subpopulations dividing at different rates among the cells 
from a same cartilage biopsy, confirming here for a whole population the previously 
reported heterogeneous growth rates of single clones (Barbero et al., 2003; Barbero 
et al., 2005). The modeling of CFSE fluorescence profiles allowed a quantification of 
these subpopulations and their precursors. As expected, the calculated precursor 
frequencies revealed an overgrowth by the fastest proliferating cells, which would 
lead to results biased towards these cells when assessing only the whole population. 
Cell division tracking with CFSE has been widely used to monitor the proliferation of 
various cell types, but was also shown to potentially have detrimental effects on cell 
behavior (Last’ovicka et al., 2009). Chondrocytes were reported to be slightly 
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affected by a 20 times higher CFSE concentration (Chawla et al., 2010), but at the 
concentrations used for this study, CFSE influenced neither their proliferation, nor 
their re-differentiation potential. Due to the broad initial coefficient of variation of 
CFSE fluorescence after chondrocyte staining (Chawla et al., 2010), individual peaks 
of cell divisions could only be visually distinguished when after sorting a gate of 
uniform fluorescence (Nordon et al., 1999). Nevertheless, even with broader initial 
fluorescence ranges, division numbers after expansion could be computationally 
resolved, which was sufficient for sorting subpopulations with only partial 
overlapping. After approximately 6 to 7 cell divisions CFSE staining became 
indistinguishable from cell autofluorescence, therefore after 1 week of expansion, 
precursor frequencies could not be determined and compared among different 
donors (Hawkins et al., 2007; Parish, 1999). This time frame was however sufficient 
to encompass the most drastic phenotypic changes (Giovannini et al., 2010). Indeed 
we found a strong link between the number of cell divisions and the expression of 
surface markers CD54, CD90 and CD166, which have been shown to characterize 
de-differentiation of proliferating chondrocytes (Diaz-Romero et al., 2005; Diaz-
Romero et al., 2008; Giovannini et al., 2010). Due to partial overlapping 
subpopulations, the resolution between cells with 0 and 1 division was not sufficient 
though to conclude whether CD90 (Thy-1) acquisition precedes or follows the first 
cell division or whether both phenomena are only coincident. The fact that only 
CD90+ cells were proliferating certainly deserves further investigation. Interestingly, 
the expression of CD49c (integrin α3) was found to increase over time, independently 
of cell doublings, which may indicate a reaction to the culture substrate (Elices, 
1991). This result together with the observed differences between native cells and 
cells with 0 to 1 division underlines that even if proliferation and de-differentiation are 
connected, phenotypical changes are caused and strongly influenced by the cell 
culture context (Minegishi et al., 2013). The expression of the specific cartilage genes 
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collagen type II, aggrecan and SOX9 decreased with increasing cell divisions, 
whereas the expression of collagen type I and versican rose. These changes in gene 
expression are considered typical for chondrocyte de-differentiation (Barbero et al., 
2003) and were reported to depend on time in monolayer culture (Giovannini et al., 
2010), but only the use of cell division tracking allowed to show that more specifically 
the phenotypic alterations progressed with individual cell divisions. 
We used different cell culture environments to analyze whether the link between cell 
divisions and de-differentiation persisted in other conditions. Remarkably, the 
expansion of chondrocytes on a hyaluronic acid in a perfusion bioreactor seeded 
scaffold resulted in a very similar cell division pattern than 2D expansion. On the 
other hand, the omission of growth factors altered cell proliferation rates, yet the 
trend of increasing de-differentiation with a higher number of cell divisions was 
conserved for all markers tested, except for CD54. In fact, in the absence of growth 
factors the latter was maintained in proliferating cells, possibly due to the absence of 
FGF-2 (Bocelli-Tyndall et al., 2015). Importantly, even if here the connection between 
cell divisions and phenotypic changes was conserved within every environment, 
comparison of growth rates among different conditions cannot be used to predict 
their relative de-differentiation or chondrogenic potential and vice-versa, because of 
the mentioned role of the cell culture context. For example the addition of growth 
factors is known to accelerate proliferation and de-differentiation, but at the same 
time preserve chondrogenic capacity in comparison to expansion without growth 
factors (Jakob et al., 2001), yet the trend of progressive changes with cell divisions 
within a same condition was demonstrated here. 
The prevention of cell spreading by alginate encapsulation or Rho small GTPase 
inhibition strongly limited chondrocyte proliferation. At the same time cells remained 
mostly CD90-, indicating that a differentiated state could be maintained. The finding 
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that even in these conditions both cell proliferation and phenotypic changes are 
interdependent indicates the strength of their coupling. Moreover it suggests that cell 
divisions and de-differentiation are possibly connected through cell morphology and 
cell spreading via the small GTPase RhoA. Indeed RhoA is not only involved in actin 
stress fiber formation, but also in cell cycle progression and cell divisions (Croft and 
Olson, 2006; Wang and Beier, 2005). Moreover RhoA was shown to influence 
chondrogenic differentiation through the expression of SOX9, the key transcription 
factor of chondrogenesis (Kumar and Lassar, 2009; Tew and Hardingham, 2006; 
Wang et al., 2004). A difference in cell morphology was observed after sorting CFSE-
labeled chondrocytes according to their number of prior cell divisions and is also 
possibly due to differences in RhoA activity (Mammoto et al., 2004). The round to 
polygonal shape observed for non-dividing cells is typically associated with 
differentiated chondrocytes, whereas the spindle-like shape of faster growing cells is 
typically seen for expanded and de-differentiated chondrocytes (Kino-oka et al., 
2005; von der Mark et al., 1977). Cell tracking or CFSE time-series taking into 
account cell death and revealing the exact kinetics of phenotypic changes could help 
to further characterization the connection between cell morphology, divisions and de-
differentiation (Etzrodt et al., 2014; Hasbold et al., 1999; Shokhirev and Hoffmann, 
2013). The question whether there is a cause-effect relationship between 
proliferation and de-differentiation namely remains open. Similarly to the hypertrophic 
differentiation during endochondral ossification in growth plate chondrocytes, 
molecular switches between proliferation and differentiation could exist (Beier, 2005; 
Chikuda et al., 2004). On the other hand proliferation and de-differentiation could be 
simultaneously activated by the culture environment through diverging pathways. If 
so, the downstream effectors of RhoA could be interesting targets to uncouple both 
phenomena (Woods and Beier, 2006). 
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We redifferentiated cells that had proliferated at different rates and observed the 
highest chondrogenic potential in cells that were slowly dividing. Cells with 0 to 1 
divisions showed less cartilaginous matrix production, despite a higher collagen type 
II to collagen type I ratio, which is generally considered as a good predictor for 
chondrogenesis (Dell’Accio et al., 2001). Possibly these cells suffered from 
alterations due to senescence that had occurred already before biopsy collection 
(Barbero, 2004). The fastest dividing cells had lost most of their potential already 
after 7 days despite the presence of growth factors known to better preserve 
chondrogenic capacity (Jakob et al., 2001). The concurrence between high cell 
proliferation rate and low re-differentiation capacity constitutes thus an important 
challenge for cartilage tissue engineering applications and underlines the importance 
of only moderate expansion for clinical applications and of finding ways to specifically 
increase the proliferation rate of slower dividing cells. Since the number of cell 
doublings was shown to be of major importance for their chondrogenic potential 
(Giovannini et al., 2010), chondrocyte subpopulations with divergent growth rates 
were further cultured until a same number of total doublings was reached. During this 
additional expansion, the growth rates were still higher for cells that were faster 
proliferating during primary culture. Although tested for only one donor our results 
indicate that the differences in chondrogenic capacity persisted, suggesting that the 
population with moderate growth rate could contain cells that have an intrinsically 
higher potential. A distinction between different cartilage zones could have helped in 
better localizing the provenance of these slow cycling cells with high chondrogenic 
potential (Dowthwaite et al., 2004; Kurth et al., 2011; Williams et al., 2010). We 
decided here to use only full thickness biopsies because this situation better mimics 
the cell source in a clinical scenario (Brittberg et al., 1994). Moreover in a previous 
study, no difference in the proliferation rate between middle and superficial zone 
chondrocytes was reported (Chawla 2010), indicating that these cells only have the 
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proliferation rate, but not the origin within a specific region of cartilage in common. In 
order to better quantify and further analyze these specific cell populations, more 
primary donors and the use of gene expression arrays will be required (Candela et 
al., 2014; Isern et al., 2014). Moreover a study of the course of proliferation and de-
differentiation of nasal chondrocytes using also additional markers like S100 could 
reveal if there are mechanistic differences explaining the higher intrinsic 
chondrogenic potential compared to articular chondrocytes (Diaz-Romero et al., 
2014; Pelttari et al., 2014). 
Based on the panel of surface markers used here, no clear phenotype of the 
moderately growing cells with higher chondrogenic potential crystallized, but in order 
to increase the cartilage forming capacity of the whole population, it could be 
sufficient to enrich the culture in cells with higher potential by sorting out quickly 
proliferating and de-differentiating cells, which were found to be CD54-
/CD90+/CD166+ after several days in culture. However as long as cell divisions and 
loss of chondrogenic capacity are strongly coupled and the cell density in tissue 
engineered constructs positively correlates with cartilage formation, a delicate 
balance between proliferation and remaining potential must be found to maximize 
graft quality. 
CONCLUSION 
Cell proliferation tracking of primary chondrocytes revealed a strong link between 
characteristic phenotypic changes and individual cell divisions, which persisted in 
different culture conditions. An increased understanding leading to an uncoupling of 
this interrelation, would open completely new perspectives for the translation of 
cartilage tissue engineering. The fact that the highest chondrogenic potential was 
found in cells that were slowly dividing, even after a same number of total doublings 
was reached, indicated that this subpopulation could be enriched in cells with an 
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intrinsically higher chondrogenic capacity. Selection of these cells with superior 
regenerative properties or elimination of fast growing cells with lower chondrogenic 
potential could help in the generation of engineered cartilage grafts with a 
reproducibly high quality. 
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ABSTRACT 
The expansion of bone-marrow mesenchymal stromal/stem cells (BMSC) on 
perfused 3D ceramic scaffolds leads to more extensive and more reproducible in vivo 
bone formation than BMSC expanded in monolayer culture on 2D polystyrene (PS). 
However, several parameters that could largely influence the in vivo osteogenic 
potential completely differ in 3D ceramic and 2D PS culture. We investigated here the 
effects on the osteogenic potential of i) the 3D scaffold vs 2D surface, ii) the ceramic 
vs PS substrate material, and iii) the extracellular matrix deposited before 
implantation. Freshly isolated bone-marrow nucleated cells were expanded on 2D PS 
dishes for 2 or 3 weeks or in perfusion bioreactors on 3D PS or 3D ceramic scaffolds 
for 3 weeks. Cells were subsequently retrieved, CD45+ depleted, and re-seeded onto 
a fresh 3D ceramic scaffold prior to implantation in an ectopic nude mouse model. 
Other cellular 3D ceramic constructs with an intact niche were directly implanted. 
After 3 weeks of culture BMSC in 3D PS and 3D ceramic had produced a dense 
extracellular matrix, but proliferated slightly less than in 2D PS. The colony forming 
efficiency remained higher in 3D than in 2D after 3 weeks. Whereas the gene 
expression in 3D PS was more similar to 3D ceramic than to 2D PS, the in vitro 
osteogenic capacity was almost identical in all conditions. In vivo, cells expanded in 
2D yielded some bone matrix, only if the culture time was not longer than 2 weeks. 
Cells expanded for 3 weeks on both 3D PS and 3D ceramic scaffolds produced a 
dense bone matrix. The number of explants containing bone was higher with cells 
expanded on 3D ceramic compared to 3D PS. However there were no appreciable 
differences between cells extracted from 3D ceramic and directly implanted 
constructs. These findings suggest that the bone-forming capacity of BMSC could be 
maintained by a combination of a 3D environment and a ceramic substrate material, 
but that a preexisting 3D niche is not required for bone formation. The preservation of 
BMSC with osteogenic potential during 3D expansion in perfusion bioreactors opens 
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the perspective for a streamlined production of large-scale bone grafts for clinical 
use. 
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INTRODUCTION 
Bone marrow-derived mesenchymal stromal/stem cells (BMSC) exhibit 
remarkable potential for use in cell and tissue therapies due to their proliferation, 
multilineage differentiation, proangiogenic, tissue homing, and immunomodulation 
capacities (1,2). In the field of bone regeneration, human BMSC hold promise for the 
treatment of a breadth of conditions including non-union fractures, osteogenesis 
imperfecta, and hypophosphatasia (3–7). Therapeutically relevant doses of BMSC 
are in the range of tens to hundreds of millions of cells, yet a 5 mL bone marrow 
aspirate only contains roughly 2,500-6,000 BMSC (8). To achieve at least a 1000-fold 
increase in cell number, BMSC are commonly expanded in monolayer on cell culture 
plastic formed from processed polystyrene (PS). However, during the requisite 
duration of expansion in 2D, BMSC demonstrate a substantial decline in progenitor 
potency (9–11). Specifically, essential properties translating directly toward 
therapeutic potential such as proliferation, multilineage potential, and colony-forming 
efficiency (CFE) are abrogated by protracted monolayer culture with serial passages 
(12,13). To exploit the optimal clinical potential of BMSC, a different expansion 
protocol that reproducibly maintains the potency of BMSC is therefore imperative. 
Recently, several studies demonstrated that expansion in an environment that 
recapitulates aspects of the native bone marrow niche better preserves the robust 
therapeutic potential of BMSC (14,15). The 2D cell culture paradigm notably lacks 
numerous qualities of the complex niche from which bone-marrow derived BMSC are 
extracted. In particular, in vivo BMSC are attached to a 3D environment composed of 
collagen and inorganic hydroxyapatite, exposed to shearing interstitial fluid 
movement, and supported by cross-talk with other cell types (13,16,17). We and 
others have expanded BMSC on 3D ceramic scaffolds in perfusion bioreactors in 
order to minimize diffusion constraints and stimulate cells in a mechanical and 
physico-chemical manner that may resemble the native bone milieu (18–23). 
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However, unlike other approaches that require an initial growth phase of BMSC on 
2D plastic, we directly seeded a minimally processed fresh bone marrow aspirate in 
the bioreactor (12,18,19). We reported that this streamlined system of 3D expansion 
under continuous perfusion consistently produces tissue constructs, which were 
osteogenic upon ectopic implantation in nude mice, unlike the counterparts 
generated from 2D expanded cells (18). We also demonstrated that the BMSC 
expanded on 3D ceramic scaffolds had enhanced progenitor properties such as 
higher clonogenicity and superior multilineage differentiation potential. Moreover, 
more than 700 genes were found to be differentially regulated between BMSC 
expanded on 2D PS dishes and BMSC expanded on 3D ceramic scaffolds under 
perfusion (19). 
Given that the bioreactor-based culture of BMSC on 3D ceramic inherently 
encompasses several aspects that are completely different than in 2D PS and could 
substantially affect the in vivo osteogenic potential, we investigated in this study the 
specific roles of i) the 3D scaffold vs 2D surface, ii) the ceramic vs PS substrate 
material, and iii) the extracellular matrix deposited before implantation. Our results 
highlight the importance of certain culture parameters for preserving the bone 
forming capacity of BMSC during expansion, which allows their further use in clinical 
applications. 
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MATERIALS AND METHODS 
Bone marrow aspirates 
Bone marrow aspirates (20 mL) were obtained from 8 healthy donors (average 
32 years old, range 17 – 50 years) after informed consent during orthopedic surgical 
procedures in accordance with the local ethical committee (University Hospital 
Basel). Nucleated cells were isolated from aspirates by lysing red blood cells with 
Ammonium Chloride Solution RBC Lysis Buffer (StemCell Technologies, USA) 
according to manufacturer protocol. The average colony forming unit-fibroblast (CFU-
F) of the fresh marrow aspirates was determined to be 0.0107% ± 0.0067%. 
 
Culture medium and conditions 
Complete medium (CM) consisted of α-MEM supplemented with 10% fetal 
bovine serum (FBS), 10 mM HEPES buffer, 1 mM sodium pyruvate, 10000 U/mL 
penicillin, and 10000 mg/mL streptomycin (all from GIBCO, Life Technologies, 
Switzerland). CM was supplemented with 10 nM dexamethasone, 0.1 mM L-ascorbic 
acid-2-phosphate (both from Sigma, USA), and 5 ng/mL fibroblast growth factor-2 
(FGF-2) (R&D, United Kingdom) to enhance BMSC proliferation and osteogenic 
priming (33,34). All cells were expanded in a humidified incubator under standard 
culture conditions (37°C, 5% CO2, 19% O2). 
 
2D expansion culture 
4x104 cells/cm2 (2D PS) or 8x103 cells/cm2(2D PS low) of freshly-isolated bone 
marrow nucleated cells were seeded on 2D polystyrene Petri dishes (BD 
Biosciences, USA) to probe the effect of seeding density on BMSC growth (19,25). 
Cells were expanded for 2 or 3 weeks without passage to examine the impact of 
culture duration and population doublings. Medium was changed twice per week, 
with preservation of non-adherent cells (35). 
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3D expansion culture 
Freshly isolated bone marrow nucleated cells were dynamically seeded via 
perfusion on 3D ceramic and 3D polystyrene 8-mm diameter scaffolds to investigate 
the role of the substrate material. Approximately 1.5x107 cells/scaffold were seeded 
onto 3D polystyrene (3D PS, 3D Biotek, USA) or 3D ceramic scaffolds (3D Cer, 
Finceramica, Italy) (20), to have similar seeding densities than for 2D cultures. 
3D seeding was performed using a perfusion bioreactor system (U-CUP, 
Cellec Biotek, Switzerland) as previously described (36). Briefly, seeded cells were 
perfused for 5 days through the scaffolds at a superficial velocity of 400 mm/s, 
corresponding to a flow rate of 1.2 mL/min. After the seeding phase, culture medium 
was refreshed and the expansion phase culture was performed at 100 mm/s, 
corresponding to 0.28 mL/min, for additional 16 days. Medium was changed twice 
per week for a total of 3 weeks in culture. Similar to 2D culture, non-adherent cells 
were re-injected. 
 
Characterization of developed niche on 3D scaffolds 
For evaluation of live cells, cellular scaffolds were sterilely retrieved from the 
bioreactors and placed in a 12-well plate with phosphate buffered saline (PBS, 
Gibco, Switzerland) to rinse away cellular debris and remnants of FBS. 
Subsequently, a 10 μM Calcein AM (Invitrogen) solution in PBS was applied for 1 
hour in standard culture conditions according to the manufacturer protocol. Scaffolds 
were rinsed again with PBS to remove stain prior to fluorescent confocal microscopy 
imaging (LSM 710, Zeiss, Germany). BMSC morphology and matrix deposition on 3D 
PS and 3D ceramic scaffolds was visualized using scanning electron microscopy 
(SEM, Nova Nano SEM 230, FEI, USA) following overnight fixation in 4% 
paraformaldehyde, dehydration, critical point drying, and gold sputtering. 
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Cell extraction and MACS cell separation 
3D expanded cells were extracted by perfusing 0.3% collagenase type II 
(Worthington, USA) through the scaffolds for 40 min followed by perfusing 0.05% 
trypsin/0.53 mM EDTA solution (Gibco, Switzerland) for an additional 15 minutes 
both at 400 mm/s. 2D expanded cells were extracted using the same enzymatic 
solutions and durations, but applied statically. Extracted cells were CD45+ depleted 
using human anti-CD45-coated magnetic beads (MACS technology, Miltenyi Biotec, 
Germany), according to manufacturer protocol. The number of extracted cells was 
assessed before and after CD45+ depletion using Neubauer counting chambers. The 
fraction of dead cells following processing, assessed by Trypan blue exclusion 
(Sigma), was negligible across experimental groups. 
 
Flow cytometry 
Before and after CD45+ depletion, expanded cells were stained with mouse 
anti-human CD90 FITC (BD Pharmigen 555595), mouse anti-human CD73 PE (BD 
Pharmigen 550257), and mouse anti-human CD45 APC (BD Pharmigen 555485). 
FITC, PE and APC isotype IgGs were used as controls (BD Biosciences). After 
washing, cells were suspended in FACS buffer consisting of 0.5% human serum 
albumin and 0.5 mM EDTA in PBS. Fluorescence was visualized with a LSRFortessa 
flow cytometer (BD Biosciences) and analyzed using FlowJo software (USA). After 
CD45+ depletion, cells used for in vitro and in vivo assays were CD45-
/CD73+/CD90+ with a purity of >99.9% in all cases (data not shown). 
 
Colony forming efficiency (CFE) 
To determine the fraction of BMSC in the fresh bone marrow aspirate, a 
colony forming unit-fibroblastic (CFU-F) assay was performed by plating 
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approximately 2.5x105 bone marrow nucleated cells per Petri dish and culturing in 
CM supplemented with FGF-2. After two weeks, colonies were rinsed with PBS, fixed 
in 4% formalin, stained with crystal violet solution (Sigma), and counted (37,38). To 
assess the colony-forming efficiency (CFE) of expanded BMSC following either 3D or 
2D expansion, 300 isolated and CD45+ depleted BMSC were plated in a Petri dish, 
cultured, stained, and analyzed similar to fresh cells. CFE was normalized within 
each donor to the 3 week expansion on 2D PS at high density seeding condition to 
adjust for donor-variability. After preliminary experiments had shown negligible losses 
during seeding and extraction, the number of BMSC population doublings was 
approximated as follows: 
𝑑𝑜𝑢𝑏𝑙𝑖𝑛𝑔𝑠 = 𝑙𝑜𝑔2
𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 × % 𝐶𝐷45−𝐶𝐷73+𝐶𝐷90+
𝑠𝑒𝑒𝑑𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 ×  𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝐶𝐹𝐸
 
 
Osteogenic potential 
The osteogenic potential of expanded BMSC was assessed by seeding 3 X 
104 cells/cm2 in a 12-well plate (TPP, Switzerland) and differentiating cells for 3 
weeks using osteogenic media, which consisted of CM supplemented with 100 nM 
dexamethasone, 10 mM β-glycerophosphate, and 0.05 mM ascorbic acid-2-
phosphate (all from Sigma). After 3 weeks, the cellular monolayer was stained with 
2% Alizarin Red S (Sigma) solution to visualize mineral deposition. Alizarin Red S 
quantification was performed by extraction with 10% cetylpyridinium chloride 
monohydrate (Sigma) for 30 minutes, after which absorbance at 540 nm was 
measured, as previously described (39). 
 
Ectopic bone formation in a murine subcutaneous tissue site 
CD45+ depleted BMSC were reseeded onto 3D ceramic scaffolds overnight at 
a superficial velocity of 400 mm/s at 2x 106 cells/scaffold, corresponding 
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approximately to the final cell density after expansion and assuring a sufficient 
number of clonogenic BMSC (12). Alternatively cells were not extracted from 3D 
ceramic scaffolds after 3 weeks of expansion were left in the bioreactor for another 
day before implantation (3D Cer direct). 
The resulting constructs were cut into quarters and ectopically implanted in the 
subcutaneous pockets of nude mice (6 weeks old female, CD-1nu/nu, Charles River, 
Germany), in accordance with in accordance with the guidelines for care and use of 
laboratory animals the University Hospital Basel, Switzerland. Four randomized 
constructs were implanted per mouse as previously describe (18). Eight weeks after 
implantation, constructs were processed by decalcification with EDTA (Sigma) and 
paraffin embedded. 5 µm thick sections were stained with hematoxylin and eosin 
(H&E) and analyzed as previously described (12). Briefly, newly formed bone tissue 
was quantified by the ratio of eosin stained dense matrix and total available pore 
space, analyzing for each construct 5 full sections spaced at intervals of 600μm 
spaced full sections per construct. 
 
Statistical analysis 
Data are presented as mean ± standard deviation using at least three 
independent donors that encompassed 3-4 technical replicates per donor. Statistical 
significance was assessed by one-way ANOVA followed by Tukey’s post hoc test for 
multiple comparisons and p-values < 0.05 were considered statistically significant. 
Categorical data for bone formation are presented as percentage and were analyzed 
with the ‘N-1’ chi-squared test (40). Statistical analysis was performed using 
GraphPad Prism®4 analysis software (GraphPad Software). 
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RESULTS 
3D expansion results in ample matrix deposition and improves colony-forming 
efficiency 
In order to investigate the influences of the 3D or 2D culture environment and 
of the substrate material, cells obtained from fresh bone marrow aspirates were 
cultured either as monolayer on 2D PS dishes or in perfused bioreactors on 3D PS 
and 3D ceramic scaffolds. Expanded cells were then extracted and CD45+ depleted 
for in vitro assessments (Fig. 1). 
 
Figure 1: Schematic of the experimental setup illustrating BMSC expansion in different conditions and 
subsequent in vitro or in vivo assessment. A fresh bone marrow aspirate was seeded and expanded 
on 2D polystyrene (2D PS) dishes for 2 weeks (2w) and 3 weeks (3w) or on 3D polystyrene (3D PS) 
and 3D ceramic (3D Cer) scaffolds for 3 weeks. Cells were extracted and CD45+ depleted, then tested 
in vitro or re-seeded overnight on a fresh 3D ceramic scaffold and implanted in vivo. A final group 
comprised a bone marrow aspirate expanded on 3D ceramic and directly implanted (3D Cer direct). 
After 8 weeks in vivo, constructs were explanted and analyzed. 
At the end of bioreactor culture 3D PS and 3D ceramic scaffolds were 
completely coated with dense extracellular matrix and viable cells were growing on 
the scaffold and in the pores (Fig. 2A). The expansion on both 3D PS and 3D 
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ceramic scaffolds for 3 weeks resulted in 2 to 3 doublings less than measured for 
BMSC expanded for the same duration in 2D, indicating an only marginally slower 
growth rate. On the other hand, in 2D culture the number of population doublings did 
slightly, but not significantly, increase from 2 to 3 weeks. Different initial seeding 
densities in 2D did not significantly impact population doublings at neither time point 
(Fig. 2B). The colony-forming efficiency (CFE) of 2D monolayer culture decreased 5 
to 6-fold when culture duration was increased from 2 to 3 weeks. In contrast, 
expansion on both 3D PS and 3D ceramic scaffolds for 3 weeks enhanced CFE 
approximately 3-fold compared to that of 2D expansion for 3 weeks, but did not 
overcome the CFE of monolayer expansion for 2 weeks. Similar to population 
doublings, differential seeding density did not significantly impact CFE (Fig. 2C). 
Since no significant difference was observed between the two seeding densities in 
2D, only the higher density was used for the following experiments. 
 
Figure 2: (A) Representative SEM images illustrating the formation of extracellular matrix in scaffold 
pores following 3 week BMSC expansion on 3D PS and 3D ceramic scaffolds. Fluorescent confocal 
microscopy images of Calcein-AM staining indicating the presence of viable cells in the pores of 3D 
PS and 3D ceramic scaffolds after 3 weeks. Scale bars are 300 µm. (B) Number of BMSC population 
doublings after 2 weeks and 3 weeks of culture on 2D PS seeded at low or normal density, and 3 
weeks on 3D PS and 3D ceramic scaffolds. (C) Colony forming efficiency (CFE) of BMSC after 
expansion, normalized for each donor to the CFE of 3 week expansion on 2D PS at normal density. 
Chart values represent mean and SD for n ≥ 3 different donors; #p<0.05 vs. 2D PS 3w. 
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Culture duration and 3D culture environment influence gene expression and in vitro 
mineralization after expansion  
The expression of genes previously shown to be differentially regulated during 
2D and 3D expansion was evaluated to identify the specific parameters affecting the 
cells on a translational level (19). The expression of AREG, CCL20 and RUNX2 
exhibited an increase from 2 weeks to 3 weeks of expansion on 2D PS, suggesting 
an influence of culture duration (Fig. 3A,B,E). On the other hand the expression of 
CXCL5 and CXCL12 was markedly different between 2D and 3D culture, which 
indicated an influence of the culture environment on gene expression (Fig. 3C,D). 
The expression of OSX was below the limit of detection in all conditions (data not 
shown), which together with the small differences in RUNX2 expression suggested 
that none of the expansion conditions primed the cells already during expansion 
towards the osteogenic lineage. The growth factor VEGF-A was similarly expressed 
in all groups, implying that the potential for promoting angiogenesis during bone 
formation was not directly affected by the culture conditions (Fig. 3F). When 
comparing the PS and ceramic 3D scaffolds, we found only negligible differences 
after expansion for all genes tested. 
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Figure 3: BMSC gene expression after expansion. For each gene, expression was normalized to the 
one of BMSC expanded for 3 weeks on 2D PS dishes: (A) Amphiregulin (AREG), (B) C-C motif ligand 
20 (CCL20), (C) C-X-C motif chemokine 5 (CXCL5), (D) C-X-C motif chemokine 12 (CXCL12), (E) 
Runt-related transcription factor 2 (RUNX2), (F) Vascular endothelial growth factor A (VEGFA). Chart 
values represent mean and SD of fold change vs. 2D PS after 3 weeks of expansion for n = 2 different 
donors; #p<0.05 vs. 2D PS. 
Expanded BMSC were also differentiated in vitro to estimate their osteogenic 
potential. Cells from all conditions were able to deposit a mineralized matrix (Fig. 
4A), however BMSC expanded for 3 weeks in both 2D and 3D regardless of scaffold 
exhibited slightly but significantly more mineral deposits than cells expanded for 2 
weeks in 2D (Fig. 4B). 
A B
C D
E F
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Figure 4: (A) Bright field microscopy images of Alizarin Red S staining of mineral deposition from 
BMSC after expansion and additional 3 weeks of osteogenic differentiation. Scale bars represent 500 
µm. (B) Quantification of Alizarin Red S, normalized to the absorbance of BMSC expanded for 3 
weeks on 2D PS. Chart values represent mean and SD for n ≥ 3 independent preparations from 1 
donor; #p<0.05 vs. 2D PS. 
3D expansion and ceramic substrate, but not matrix deposition, potentiate bone 
formation in vivo 
The in vivo bone formation potential of 2D and 3D expanded BMSC was 
assessed by either re-seeding of CD45- sorted cells onto a fresh ceramic scaffold 
and subsequent implantation, or by direct implantation of the cells grown on the 
ceramic scaffold (Fig. 1). H&E staining of explants after 8 weeks revealed bone 
formation in constructs from all groups except for cells expanded for 3 weeks on 2D 
PS dishes, as evidenced by intensively stained areas of dense matrix (Fig. 5A). 
Explants derived from acellular 3D ceramic scaffolds did not show any bone 
formation via H&E (data not shown). The percentage of osteogenic explants 
generated from cells expanded on 3D ceramic scaffolds was substantially higher 
than for cells grown on 2D dishes for 2 or 3 weeks. BMSC expanded on 3D ceramic 
2D PS 2w 2D PS 3D PS 3D Cer
A
B
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scaffolds also gave rise to more osteogenic constructs than cultured on 3D PS 
scaffolds. However, no difference was observed in the frequency of constructs with 
evident bone formation between cells extracted from 3D ceramic and constructs 
implanted with a conserved extracellular matrix and CD45+ population (Fig. 5B). 
Considering only the osteogenic constructs in each condition, the quantified area of 
bone formation was variable but on average not significantly different among all 
groups tested (Fig. 5C). 
 
Figure 5: Expanded cells were CD45+ depleted, re-seeded onto a fresh 3D ceramic scaffold and 
implanted in an ectopic nude mouse model. Alternatively 3D ceramic constructs with an intact 
extracellular matrix were directly implanted. (A) H&E stained histological sections of explants with 
intensively stained areas of dense matrix, indicating bone formation in constructs from all groups 
except for cells expanded for 3 weeks on 2D PS dishes. A representative slide is shown for each 
group. Scale bars are 200 µm. (B) Osteogenic constructs as a percentage of total implants. Bone 
formation was identified by the presence of matrix positive for eosin (2D PS 2w: n=8, 2D PS: n=11, 3D 
PS: n=7, 3D Cer: n=7, 3D Cer direct: n=11). (C) Quantified area of bone formation as a fraction of 
available pore space and group average (horizontal bar), considering only the osteogenic explants in 
each condition. For each construct 5 full sections spaced at intervals of 600μm were analyzed. Data 
points represent averages of constructs. 
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DISCUSSION 
We previously validated the implementation of a streamlined system for the 
expansion of fresh bone marrow aspirates, which employs 3D ceramic scaffolds in 
perfusion bioreactors to entirely bypass cell culture on 2D plastic, by demonstrating a 
more reproducible and more extensive bone formation in vivo (18). In the present 
study, the discrepancy between 2D PS dishes and 3D ceramic scaffolds was bridged 
via a 3D PS scaffold in order to investigate separately the fundamental roles of the 
culture dimensionality and the substrate material on the bone formation potential. 
Results showed that after 3 weeks of culture BMSC in 3D PS and 3D ceramic had 
proliferated slightly less than in 2D PS, but that their colony forming efficiency (CFE) 
remained higher. Whereas the gene expression in 3D PS was more similar to 3D 
ceramic than to 2D PS, the in vitro osteogenic capacity was almost identical in all 
conditions. Considerable differences were found for the osteogenic capacity in vivo, 
where cells expanded in a perfused 3D environment, both on PS and on ceramic 
scaffolds, were able to produce a dense bone matrix. The number of osteogenic 
explants was higher when generated from cells cultured on 3D ceramic than from 3D 
PS, implying that besides the 3D environment also the substrate choice was relevant 
to maintain a higher bone formation potential. Moreover we observed no differences 
in bone formation between cells extracted from 3D ceramic and directly implanted 
constructs, which challenges the necessity of a preformed extracellular matrix for 
osteogenesis. 
Substantial cell expansion is required to achieve a sufficient number of BMSC 
for clinical applications and in addition to the presence of growth factors other 
parameters could strongly influence proliferation kinetics (1). Our findings suggested 
that the 3D culture environment was a more important factor for the doubling rate and 
the CFE of BMSC than the difference in substrate materials. Population doublings 
and CFE are likely intertwined and for expanded BMSC the plating density has been 
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reported to affect CFE (9,24,25). We therefore included additional 2D PS groups with 
shorter culture periods and lower seeding densities and found important changes in 
CFE due to culture duration, but not seeding density. The fact that cells in 2D PS 
dishes approached confluence towards the end of the culture could partially explain 
the slower growth rate during the 3rd week and could also have affected CFE (9). On 
the other hand a recent study showed that confluence did not to alter the BMSC 
phenotype (26). 
In our previous transcriptomic analysis of BMSC expanded in plastic dishes or 
perfused ceramic scaffolds, we reported differences in the expression of more than 
700 genes (19). For the genes tested here, we confirmed the disparity between 2D 
PS and 3D ceramic expansion, but only small differences were detected between 3D 
PS and 3D ceramic, which was in agreement with prior data showing that perfused 
bioreactors allow a robust expansion process with reduced variability (19). 
Interestingly, more pronounced changes were found in the expression profiles from 
week 2 to week 3 in 2D PS corroborating reports that phenotypical differences of 
BMSC can arise from the culture environment as well as culture duration (22,27). 
Rather than the in vitro assessments, the ectopic implantation of scaffolds 
seeded with 2D or 3D expanded cells revealed dramatic differences in their bone 
formation capacity. Cells were implanted directly after expansion, without additional 
osteogenic induction, in order to assess their intrinsic capacity for bone formation 
(28). Remarkably, we found that a perfused 3D environment was sufficient for the 
maintenance of osteogenic potential during proliferation, even if the scaffold was 
made of PS. The ceramic substrate, which is thought to prime BMSC towards the 
osteogenic lineage (29), further reinforced this effect and lead to a reproducible bone 
formation. To further elucidate the relative contribution of the environment and the 
substrate to the maintenance of osteogenic potential, a 2D ceramic material or PS 
and ceramic 3D scaffolds with exactly identical geometries could be used. 
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Even if bone formation with cells expanded for 2 weeks in 2D PS was 
possible, the evident decline of osteogenic potential and CFE during an additional 
week of culture showed that this environment could not preserve progenitor 
properties. For the prolonged maintenance of native BMSC such as required by in 
vitro models of bone-marrow (15), perfused 3D ceramic scaffolds could therefore be 
the more promising system. Interestingly the amount of bone area in osteogenic 
constructs was variable among the groups tested. Since in all constructs the density 
of clonogenic BMSC was above the previously found threshold (12), the underlying 
reasons for the heterogeneous bone area and for the absence of bone formation in 
part of the constructs from one same group remain unknown. The fact that cell 
doubling number, RUNX2 expression and in vitro mineral deposition did not at all and 
CFE only partially predict the resultant capacity for bone formation is noteworthy 
because these assays are frequently used to quantify BMSC progenitor potency (13). 
Numerous facets of the bone marrow niche, which precisely regulate BMSC 
phenotype (15,30), are egregiously lacking in 2D culture on plastic. Since bioreactor 
expansion on 3D scaffolds facilitated extensive extracellular matrix production (18), 
we investigated whether BMSC extracted from their 3 week developed niche would 
generate comparable bone in vivo to directly implanted scaffolds. However no 
significant differences were found between these groups, indicating that the 
osteogenic potential of expanded BMSC does not depend on the presence of a niche 
at the moment of implantation. This implies that if BMSC are required for cell therapy, 
they could be expanded on 3D ceramic, subsequently retrieved, and re-implanted 
without loss of osteogenic potential. On the other hand additional experiments would 
be required to investigate the effect on BMSC progenitor properties of a niche 
present during expansion. 
With the extended knowledge on the importance of the three-dimensionality 
and the ceramic material, enhanced strategies can be developed to sufficiently 
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expand BMSC while maintaining their potential to yield functional grafts for improved 
treatments of patients. Furthermore rapid-prototyped scaffolds made from 
polystyrene such as the one used for this study could help to investigate other cell 
types that have been shown to grow differently in 2D and 3D environments, 
independently of the influences of an extracellular matrix (31). Besides solely being 
used for cell expansion, the perfused bioreactors could thereby serve as a model 
system to study cell phenotypes or interactions among different cell types under 
more controlled conditions (32). 
 
CONCLUSION 
In this work we decoupled two eminent parameters of adherent cell culture, 
the substrate dimensionality and material, to study their individual effects on the 
capacity of BMSC to form bone after expansion. We demonstrated that in contrast to 
2D plastic the use of a perfused 3D plastic scaffold was sufficient to maintain the in 
vivo osteogenic potential and that this effect could be further reinforced in 
combination with a ceramic substrate. Furthermore the preexistence of a 3D niche of 
extracellular matrix in which the expanded cells were embedded was not required for 
subsequent bone formation. These results underline the importance of a 3D culture 
environment to preserve the differentiation potential of BMSC. From a clinical 
perspective, the use of perfusion bioreactors thereby offers the possibility to expand 
osteogenic cells and to generate robust bone grafts in a reproducible and 
streamlined process. 
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ABSTRACT 
The introduction of automation for the manufacturing of engineered cartilage will be 
crucial to standardize production methods and to maximize prospective scale-up and 
cost-effectiveness in the long-term. However, the limited stability of some bioactive 
supplements currently used in cartilage engineering, such as growth factors and 
vitamins, requires specific components to be stored at different temperatures and 
poses significant challenges to the automation of liquid handling. Ascorbic acid is 
generally considered to be a critical supplement for cartilage tissue engineering 
because of its role in collagen hydroxylation. Due to its instability, ascorbic acid is 
typically added from frozen aliquots at each medium change, preventing 
straightforward automation. The aim of this study was to investigate the effect of 
ascorbic acid on the gene expression and extracellular matrix production of human 
nasal chondrocytes, with special regard to collagen synthesis and hydroxylation, in 
order to define appropriate requirements for automation strategies. Results showed 
that cartilage gene expression, pellet formation, and glycosaminoglycans deposition 
were indistinguishable whether chondrocytes were cultured with or without ascorbic 
acid. Not adding ascorbic acid caused a 35% reduction of type II collagen in the 
matrix, whereas hydroxylation of total collagen was not significantly affected. 
Chondrocytes did not exhibit impaired secretion of collagens and the extracellular 
matrix showed a similar organization and structure of collagen fibrils in the presence 
and absence of ascorbic acid. In conclusion, ascorbic acid did not influence 
chondrogenesis except for a limited effect on collagen deposition, and could thus be 
omitted to simplify automated manufacturing.  
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INTRODUCTION 
Engineered cartilage grafts have been reported in preclinical and clinical studies to 
be a promising treatment for the biological resurfacing of acute and chronic joint 
lesions (1–3). For their widespread implementation as therapeutic option, the high 
manufacturing expenses generally associated with cartilage tissue engineering need 
to be considerably decreased (4,5). In this regard, bioreactors have been suggested 
as suitable means allowing cost reduction by automation, standardization, and 
scalability (6–8). However, the straightforward automation of bioreactors for cartilage 
tissue engineering is considerably hindered by the complex liquid handling and 
storage conditions imposed by unstable compounds currently used in most 
chondrogenic culture medium formulations.  
Ascorbic acid (AA) is a bioactive supplement, which can be rapidly oxidized to 
dehydroascorbic acid and further irreversibly degraded by oxidation or hydrolysis, 
resulting in short-time availability (9–11). Several AA derivatives with protective 
groups against degradation have been developed, such as the more stable but 
equally bioactive ascorbic acid-2-phosphate (AA2P) (12). Still, the latter is typically 
added from frozen aliquots at every medium exchange, which drastically complicates 
bioprocess automation due to the required additional freezing compartment as well 
as the thawing and supplementation machinery and procedures. 
Besides being a notable antioxidant, AA is involved in the synthesis of collagens, 
amongst others type II collagen, a key protein of hyaline cartilage (13). In particular 
AA serves as a co-factor for the enzymes prolyl hydroxylase and lysyl hydroxlase, 
which are responsible for the hydroxylation of proline and lysine residues of the 
collagen propeptide. This hydroxylation is essential for the cross-linking of alpha 
peptides and collagen triple helix stability (14–16). Moreover AA is thought to induce 
chondrogenesis via an upregulation of collagen expression and is therefore added in 
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most protocols for chondrogenic differentiation (17–19). Nevertheless, it was shown 
that other available molecules could replace AA as a cofactor and antioxidant in cell-
free systems, guinea pigs and for other prolyl-4-hydroxylase domain–containing 
enzymes (14,15,20–22). Additionally, the recycling of AA from dehydroascorbic acid 
after uptake via glucose transporter 1 was reported for chondrocytes (23,24). 
The possibilities for substitution and recycling suggest that the addition of AA might 
not be strictly necessary for the generation of a hyaline cartilage-like extracellular 
matrix. We therefore hypothesized that chondrocytes can synthesize collagens with 
hydroxylated proline residues and produce a cartilaginous extracellular matrix rich in 
GAG in the absence of AA. With a better knowledge of the AA requirement of 
chondrocytes during in vitro cartilage graft manufacturing, efficient supplementation 
schemes can be implemented that simplify the necessary automation, while ensuring 
adequate product quality. 
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MATERIALS AND METHODS 
Ascorbic acid measurements 
AA2P was quantified in medium stored at 4 or 37°C for up to 14 days and in spent 
medium from pellet cultures using the ferric reducing ascorbate assay kit (FRASC; 
BioVision, Switzerland), according to the manufacturer’s instructions with an 
additional step to be able to measure the 2-phosphate form. Briefly, to transform 
AA2P into measurable AA, samples were first incubated with 1 unit/100 µl of alkaline 
phosphatase (Sigma, Switzerland) for 10 min at 37°C. This step was omitted when 
measuring the medium concentration of AA molecules without a 2-phosphate group. 
Ascorbate oxidase or water was then added to generate the AA depleted background 
or the total oxidant group, respectively. After addition of the ascorbic acid reaction 
mix, absorbance at 593 nm was measured and the concentration of AA2P or AA was 
calculated from the difference of the total oxidant and the AA depleted group with the 
help of an AA standard curve. 
Cell isolation and culture 
Samples of human cartilage were collected from the nasal septum of 10 patients 
undergoing rhinoplasty (Mean age 37 years, range 21 – 63 years), after informed 
consent and in accordance with the local ethical commission (University Hospital 
Basel). Overlaying perichondrium was carefully removed and cartilage biopsies were 
digested using 0.15% collagenase II (Worthington, UK) during 22 h at 37°C as 
previously described (25). After digestion, cells were plated in tissue culture flasks at 
a density of 1x104 cells/cm2 and cultured in complete medium (CM) consisting of 
Dulbecco's modified Eagle's medium containing 4.5 mg/ml D-glucose and 0.1 mM 
nonessential amino acids (DMEM, Gibco, Life Technologies, Switzerland), 10% fetal 
bovine serum (FBS), 1 mM sodium pyruvate, 100 mM HEPES buffer, 100 U/ml 
penicillin, 100 μg/ml streptomycin, and 0.29 mg/ml L-glutamine (all from Gibco), 
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supplemented with 1 ng/ml transforming growth factor beta 1 and 5 ng/ml fibroblast 
growth factor 2 (both from R&D Systems, UK) at 37°C and 5% CO2 in a humidified 
incubator (Thermo Scientific Heraeus, USA) (26). When approaching 80% 
confluence, cells were detached using 0.05% trypsin-EDTA (Gibco), resuspended in 
FBS containing 10% dimethyl sulfoxide, filled in cryovials (Sarstedt, Germany) and 
stored in liquid nitrogen tanks until further use. 
Chondrogenic re-differentiation 
Chondrocytes from frozen aliquots were expanded until passage 2 and re-
differentiated by culturing 5x105 cells for 2 weeks as micromass pellets, formed by 
centrifugation at 300xg in conical 1.5-ml tubes (Sarstedt), in chondrogenic serum-free 
medium (SFM) consisting of DMEM containing 1 mM sodium pyruvate, 100 mM 
HEPES buffer, 100 U/ml penicillin, 100 μg/ml streptomycin, and 0.29 mg/ml L-
glutamine, 1.25 mg/ml human serum albumin, 100 nM dexamethasone (Sigma), and 
10 ng/ml TGF-β1 (R&D Systems), with addition of ITS+1 (10 µg/ml insulin, 5.5 µg/ml 
transferrin, 5 ng/ml selenium, 0.5 mg/ml bovine serum albumin, 4.7 µg/ml linoleic 
acid; Sigma, Switzerland), with or without 100 µM ascorbic acid 2-phosphate (Sigma) 
(+ AA2P / - AA2P). Chondrogenic culture medium was changed twice weekly (27). 
No chondrogenic induction was provided in one group, culturing pellets in the 
absence of ITS+1 (- AA2P - ITS). For an additional experimental group AA2P was 
supplemented every day after quantification to maintain a constant concentration of 
100 µM (daily AA2P). 
Histology and immunohistochemistry 
Micromass pellets were fixed overnight in 4% formalin and embedded in paraffin. 5 
µm thick sections were stained with Safranin-O for sulfated glycosaminoglycans 
(GAG) with hematoxylin as nuclear counterstaining (27). Immunohistochemistry 
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against type I and type II collagen (both from MPBiomedicals, France) was performed 
using the Vectastain ABC kit (Vector Labs, USA) and counterstaining with 
hematoxylin as previously described (28). Terminal deoxynucleotidyl transferase 
dUTP nick end labeling with an Alexa Fluor 647 dye (Click-iT TUNEL assay; 
Molecular Probes, Switzerland) was performed on formalin-fixed paraffin-embedded 
sections, according to the manufacturer’s instructions. A positive control with DNA 
strand breaks was generated by 30 min incubation at room temperature with 1 unit of 
DNase I (Molecular Probes). Immunofluorescence staining against type II collagen 
was performed on OCT (CellPath, UK) embedded 10 µm thick cryosections using a 
mouse type II collagen primary antibody (MPBiomedicals) and a goat anti-mouse 
Alexa Fluor 546 secondary antibody (Invitrogen), with DAPI as a nuclear 
counterstain.  
Quantitative RT-PCR 
mRNA of chondrocytes was extracted using Quick-RNA Miniprep (Zymo Research, 
USA), according to the manufacturer’s protocol. DNaseI (Zymo Research) was used 
to remove trace DNA. Isolated RNA was quantified using a NanoDrop 
spectrophotometer (ThermoFischer Scientific). Reverse transcription into cDNA was 
done from 3 μg of RNA by using 500 μg/ml random hexamers (Promega, 
Switzerland) and 0.5 μl of 200 UI/ml SuperScript III reverse transcriptase (Invitrogen), 
in the presence of dNTPs. Quantitative real-time PCR was carried out on an ABI 
Prism 7700 Sequence Detection System (Perkin-Elmer/Applied Biosystems, 
Switzerland). After initial denaturation at 95°C for 10 min, cDNA was amplified for 40 
cycles, each consisting of a denaturation step at 95°C for 15 s and an 
annealing/extension step at 60°C for 60 s. Primers and probes for aggrecan, 
versican, collagen type I, collagen type II and GAPDH were used with TaqMan Gene 
Expression Master Mix (Applied Biosystems) as previously described (29). Assay on-
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Demand (Applied Biosystems) was used to measure the expression of SOX9 
(Hs00165814_m1). The threshold cycle (Ct) value of the reference gene GAPDH was 
subtracted from the Ct value of the gene of interest to derive ΔCt. The relative gene 
expression of each group normalized to the cells after expansion was calculated as 2-
ΔΔCt. Each sample was assessed at least in duplicate for each gene of interest. 
Biochemical analyses 
Micromass pellets were digested in proteinase K (1 mg/ml proteinase K in 50 mM 
Tris with 1 mM EDTA, 1 mM iodoacetamide, and 10 mg/ml pepstatin A) for 16 h at 
56C. The glycosaminoglycan content of pellets was determined by 
spectrophotometry using dimethylmethylene blue, with chondroitin sulphate as a 
standard (30). The DNA content of pellets was measured using the CyQuant cell 
proliferation assay kit (Invitrogen), with calf thymus DNA as a standard. The amount 
of GAG in pellets was then normalized to the DNA content (27). 
For hydroxyproline quantification, samples were processed as previously described 
(18,31). Briefly, proteinase K digested samples were mixed with equal amounts of 
12M HCl and hydrolysed at 120°C for 24h. Specimens were then transferred into 96-
well plates and left to dry before addition of acetate-citrate buffered chloramine T and 
incubation for 20 min at room temperature. Dimethylaminobenzaldehyde was added 
and the plates heated for 20 min to 60°C. Absorbance was then measured at 550nm. 
Concentrations were calculated with the help of a hydroxyproline (Sigma) standard 
curve. 
Collagen quantification 
Pellets were solubilized by an initial digestion in 25 µl of 2 mg/ml TPCK-treated 
bovine pancreatic trypsin (in 50 mM Tris HCl pH 7.5, 1 mM EDTA, 1mM 
iodoacatamide, 20 µg/ml Pepstatin A), for 15 h at 37 °C. A further 25 µl of freshly 
prepared trypsin solution was added, and digests were incubated for 2 h at 65 °C, 
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with intermittent vortexing. Digests were then boiled for 15 min to destroy remaining 
enzyme activity. The quantity of type II collagen was determined using an inhibition 
ELISA with a mouse IgG monoclonal antibody to denatured type II collagen (32). 
Type I collagen was measured by inhibition ELISA using a rabbit anti-peptide 
antibody to type I collagen (33). 
Scanning electron microscopy 
For scanning electron microscopy (SEM), pellets were fixed for 2 days in 0.1 M 
cacodylate-buffered 2% glutaraldehyde at pH 7.2 at 25°C, then glued onto a Teflon 
disc with a rapidly curing epoxy glue (Araldite; Huntsman, UK). Next the specimens 
were placed in a cryostat microtome to trim off the outermost, approximately 150 μm 
thick cartilage layer parallel to the support surface to assess the central part of the 
samples. In a next step, proteoglycans were extracted in 100 mM Soerensen's 
phosphate buffer (pH 7.2) containing 1 mg/ml bovine hyaluronidase (type I, Sigma), 1 
mg/ml trypsin (type I, Sigma) and 0.01% NaN3 at 37°C for 3 days. After dehydration 
in graded ethanol series and critical point drying, samples were sputter-coated with 
3–5 nm platinum and examined by SEM (Hitachi S-4800 FEG, Japan), operated at 
1.5–5 kV accelerating voltage in immersion mode (34,35).  
Statistical analysis 
Data are presented as mean and standard deviation of independent experiments with 
cells from at least 2 different donors. For each analysis at least 3 replicate micromass 
pellets were used per condition. Statistical analysis was performed with Prism 
software (GraphPad Software, USA) using one-way ANOVA followed by Tukey’s post 
hoc test for multiple comparisons. Values of p < 0.05 were considered statistically 
significant. 
  
 119 
 
RESULTS 
AA2P stability 
In order to test the availability of AA in chondrogenic medium formulations, the 
stability of AA2P was assessed in stored medium with or without fetal bovine serum. 
Whereas in serum-free conditions the concentration of AA2P was constant over 2 
weeks, both at 4°C and 37°C, the presence of serum lead to rapid AA2P 
degradation. AA2P appeared to be particularly unstable when stored in serum 
containing medium at 37°C, dropping to less than 10% of the initial concentration 
within 24 hours (Fig. 1A). Since AA2P was stable only in the absence of serum, we 
performed all following cell culture experiments in serum-free conditions. When 
culturing micromass pellets, the concentration of AA2P decreased by almost 50% 
during the first 24 hours of culture and further declined to less than 25% by day 3 
(Fig. 1B). A higher, relatively constant concentration of 100.6 ± 26.6 µM AA2P could 
be maintained by daily supplementation of AA2P. Interestingly, the concentration of 
AA deprived of the protective 2-phosphate group was below the limit of detection in 
stored and pellet culture medium at all time points, indicating immediate further 
degradation or consumption (not shown). 
 
Figure 1: Availability of ascorbic acid 2-phosphate in stored medium and micromass pellet 
culture. (A) Concentration of ascorbic acid 2-phosphate (AA2P) in serum-free medium (SF) or 10% 
fetal bovine serum-containing medium (CM) stored at 4°C or 37°C for up to 14 days, showing a fast 
degradation in the presence of serum. (B) Concentration of AA2P in spent serum-free medium of 
micromass pellet culture, revealing progressive rapid decrease over 3 days. 
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Cell viability in pellet culture 
Since AA is a potent antioxidant that prevents oxidative stress in cells, the effect of its 
absence on cell viability was tested in chondrocyte pellet culture. Terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) revealed only few 
events of DNA fragmentation across all conditions, indicating that the vast majority of 
cells were alive even in the absence of AA2P (Fig. 2A). The quantification of DNA 
showed very similar quantities in the pellets from all conditions, suggesting that no 
significant decrease in cell mass occurred when cells were cultured without AA2P 
and that no additional protection was provided when the antioxidant was present at a 
higher concentration (Fig. 2B). 
Figure 2: Cell viability and cell mass. (A) Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL; red, indicated by asterisk *) and DAPI nuclear counterstain (blue) of histological 
sections of micromass pellets after 2 weeks of chondrogenic culture in the presence or absence of AA. 
The few TUNEL-positive DNA strand breaks indicate rare events of cell necrosis or apoptosis in all 
culture conditions. Scale bar 50 µm. (B) DNA quantification of micromass pellets cultured with or 
without AA, indicating similar cell masses. 
 
 
 
B
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Gene expression and glycosaminoglycan deposition 
Nasal chondrocytes showed an upregulation in the expression of collagen type II, 
aggrecan and Sox9, which was similar when comparing chondrocytes cultured in 
chondrogenic medium with or without AA2P (Fig. 3A). This finding indicated that the 
induction of chondrogenesis did not depend on the presence of AA2P in the culture 
medium. Histological sections of micromass pellets revealed a cartilaginous 
extracellular matrix with a similar cellularity and distribution of glycosaminoglycans 
(GAG) in the presence and in the absence of AA2P, as displayed by uniform 
Safranin-O staining. In the case where ITS was not supplemented, pellets were much 
smaller and had little extracellular matrix that was not positively stained for GAG (Fig. 
3C). These findings were further substantiated by the quantification of the amount of 
GAG per DNA. Compared to the standard condition with supplementation of AA2P at 
each medium change, neither the absence of AA2P nor the maintenance of a higher 
AA2P concentration resulted in significant changes in the GAG/DNA ratio. On the 
other hand, the omission of ITS drastically reduced the production of GAG (Fig. 3B). 
 
C
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Figure 3: Gene expression and glycosaminoglycan production. (A) Gene expression after 2 weeks 
of chondrogenic differentiation with or without ascorbic acid as fold increase relative to expanded cells, 
showing similar upregulation of collagen type II, aggrecan and SOX9. (B) GAG/DNA ratios of 
micromass pellets normalized to the condition with ascorbic acid of the same donor. GAG production 
was similar in all conditions except for the pellets cultured without ITS (* p < 0.05). (C) Safranin-O 
staining of histological sections of micromass pellets revealing the production of an extracellular matrix 
rich in glycosaminoglycans, except for pellets cultured without ITS. Scale bar 200 µm. 
 
Distribution of collagens and quantification of collagens and hydroxyproline 
As AA is a cofactor in the hydroxylation of proline during collagen synthesis, we 
tested the effects of its absence on collagen deposition and hydroxylation. 
Immunohistochemistry revealed that chondrogenic pellets contained collagens type I 
and type II independently of the addition of AA2P, but not in the absence of ITS. 
Whereas collagen type I was distributed mainly on the edge of the pellets, collagen 
type II was abundantly present in the extracellular matrix of the whole pellet, except 
for a thin outer rim (Fig. 4). 
 
Figure 4: Collagen type I and collagen type II distribution. Histological sections of micromass 
pellets stained by immunohistochemistry against collagen type I or collagen type II. Matrix positive for 
collagen type I was found on the edge of the pellets, whereas collagen type II was located in the whole 
pellet except for a thin external rim. None of the collagens was found is pellets cultured without ITS. 
Scale bar 200 µm. 
 
Quantification of collagens type I and type II by specific immunoassays confirmed 
deposition of both proteins in the absence of ascorbic acid. Relative to the addition of 
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AA2P, the amounts of collagens type I and type II secreted in cultures without AA2P 
were reduced by 50% and 34%, respectively. Daily AA2P did not lead to a substantial 
change in collagens quantity, while pellets maintained without ITS contained almost 
no collagen type I and significantly reduced levels of collagen type II (Fig. 5 A,B). The 
post-translational hydroxylation of collagens was confirmed by quantification of 
hydroxyproline in pellets from all groups, although the amount per pellet was reduced 
in the absence of AA2P compared to the groups with AA2P and daily AA2P addition 
(Fig. 5 C). The ratio of hydroxyproline/collagen was not significantly reduced in the 
absence of AA2P and the maintenance of a higher concentration of AA2P did not 
lead to an increased percentage of hydroxylation compared to supplementation only 
during medium exchange. In the group without ITS, only background levels of 
hydroxyproline were measured. As a result, the reduced amounts of collagens 
detected were also underhydroxylated (Fig. 5D). 
 
Figure 5: Collagen type I, collagen type II, and hydroxyproline quantification. (A) Quantification of 
collagen type I. (B) Quantification of collagen type II. (C) Quantification of hydroxyproline. (D) Ratio of 
hydroxyproline to collagen. All normalized to the value of the condition with ascorbic acid of the same 
donor (* p < 0.05). Results show that collagens type I and type II were produced in the absence of 
ascorbic acid and had a similar ratio of hydroxylation/collagen. 
A B
C D
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Collagen secretion 
Since the slight reduction of collagen amounts in spite of similar gene expression 
could have resulted from impaired secretion in the absence of AA2P, we used high 
magnification immunofluorescence to assess whether collagen type II accumulated 
intracellularly. Images showed that collagen type II was evenly distributed in the 
extracellular matrix and no aggregation of type II collagen close to the nucleus was 
observed, independently of the presence or absence of AA2P. In case of the 
omission of ITS, no collagen type II was detected, which confirmed the results found 
by immunohistochemistry (Fig. 6). 
 
Figure 6: Collagen type II immunofluorescence and scanning electron. (A) Cryosections of 
micromass pellets stained by immunofluorescence against collagen type I (red) and DAPI nuclear 
counterstain (blue). Scale bar 10 µm. (B) Scanning electron microscopy of micromass pellets after 
digestion of glycoproteins showing collagen fibril network. Scale bar 200 nm. 
 
Collagen fibril network structure 
We investigated next whether the absence of AA2P had an effect on the structure 
and arrangement of collagen fibrils. High magnification scanning electron microscopy 
showed no collagen fibrils in the absence of ITS, but a similar fibril distribution, 
thickness and alignment when chondrocytes were cultured with or without AA2P. 
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This finding visually confirmed that in the absence of AA2P intact collagen fibers with 
normal appearance were secreted. Moreover it indicated that the absence of AA2P 
did not impair the formation of a dense network formed by single collagen fibrils (Fig. 
6). 
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DISCUSSION 
The present study showed that AA2P was stable in serum-free culture medium when 
stored at 4 or 37°C, but it was fast degraded in the presence of serum and rapidly 
decreased in serum-free pellet culture. The omission of AA2P in chondrogenic pellet 
culture did not lead to increased cell death. Gene expression, pellet formation, and 
glycosaminoglycans deposition were indistinguishable whether chondrocytes were 
cultured with or without AA2P. Type I and type II collagens were produced also in the 
absence of AA2P, even if to a lower extent. The ratio of hydroxyproline/collagen was 
unchanged in the absence of ascorbic acid. Chondrocytes did not exhibit impaired 
secretion of collagens and the extracellular matrix showed a similar organization and 
structure of collagen fibrils in the presence and absence of AA2P. 
AA is known to be an unstable component of cell culture medium due to a fast 
degradation process catalyzed by iron and copper ions (11). The AA derivative AA2P 
was shown to be more stable and to have the same bioactivity than AA (12). The 
increased stability of AA2P with its protective phosphate group strongly depends on 
the culture conditions and thus needs to be assessed in each case. Our results 
proved the stability of AA2P in serum-free medium for up to 2 weeks when stored 
both at 4 and 37°C. However, the stability of AA2P was drastically reduced in serum-
containing medium, likely due to the presence of phosphatases (9). AA2P 
concentration was rapidly reduced also in serum-free medium when culturing 
chondrocytes in micromass pellets: membrane-bound or secreted phosphatases 
likely degraded AA2P to AA, which was then further degraded or taken up by the 
cells (12). In the culture conditions tested, daily addition of AA2P was required to 
maintain constant concentration of AA2P. Overall, the collected results highlight the 
need to assess the availability of AA2P in the specific culture conditions/experimental 
setup, in order to define the most appropriate strategy to ensure the required levels 
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(e.g., sustained supply through continuous addition, more frequent medium change 
or larger volumes). 
The potent antioxidative effect of AA consists in scavenging reactive oxygen and 
nitrogen species (36,37). The observed absence of apoptosis and necrosis in 
micromass cultures, suggests that AA was not required to prevent oxidative stress 
and that probably the presence of endogenous oxidants such as glutathione sufficed 
(38). The TUNEL assay was considered to be a more adequate indicator of the 
actual effects of the absence of AA, rather than the unreliable direct quantification of 
reactive oxygen species (39,40). 
The absence of AA in pellet culture did not affect the expression of cartilage specific 
genes, which is in contrast to earlier studies claiming AA-induced upregulation of 
collagen synthesis on a translational level (41–43). Moreover, the extracellular matrix 
formed without AA was dense and rich in proteoglycans. In humans and guinea pigs, 
dietary AA deficiency leads to severe defects in connective tissues, known as scurvy, 
attributed to an impaired collagen synthesis due to insufficient proline hydroxylation 
(15). In the present study we found that chondrocytes could produce collagen type I 
and type II proteins in the absence of AA. The secreted amounts were only slightly 
reduced compared to the culture with AA and considerably higher than without 
chondrogenic induction. Quantification by immunoassay allowed a specific detection 
independent of the hydroxylation of the collagen proteins, which was also shown to 
be more precise than histological grading (32,33). The quantity of hydroxyproline per 
pellet was inferior in the absence of AA, confirming that AA had an effect on proline 
hydroxylation (44). However the amount of hydroxyproline per collagen was only 
marginally less in the absence of collagen, indicating that the enzyme proline 
hydroxylase was largely functional. Altogether these findings are in agreement with 
studies challenging the essentiality of AA as a co-factor for prolyl hydroxylase in 
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certain conditions. In fact, mutant mice lacking the final enzyme for AA synthesis 
were recently shown to have a normal collagen production and the absence of AA 
had no direct effect on collagen hydroxylation in guinea pigs (45,46). Probably other 
molecules present in the medium such as glutathione or cysteine can compensate for 
the lack of a co-factor, even if at a lower activity (14). Alternatively AA could be 
recycled over long durations, which could also explain why proper collagen 
production without ascorbic acid supplementation was observed in vivo (23,24). The 
discrepancy with previous studies showing a strong effect of AA on gene expression, 
collagen synthesis and hydroxylation might derive from the use of different culture 
conditions and need further investigation (17,18,41–43,47,48). The above-mentioned 
substitute molecules could be absent in certain medium preparations or certain cell 
types may be incapable of AA recycling. Interestingly, no increase in collagen 
deposition or hydroxylation per collagen was observed when maintaining a constant 
concentration of ascorbic acid: this data indicate that the applied regime of medium 
exchanges was sufficient to reach saturation of AA-dependent mechanisms in our 
specific setting. The differences in the quantity of collagen deposition between 
groups, despite a similar gene expression and similar hydroxyproline/collagen could 
have resulted from a slower secretion. In fact an accumulation in the endoplasmic 
reticulum has been reported for insufficiently hydroxylated collagens, which could be 
the case here as a consequence of the lower activity of alternative co-factors (49,50). 
However, intracellular collagen accumulation indication of impaired secretion could 
not be detected using high magnification immunofluorescence (50). 
The unique biomechanical features of articular cartilage largely depend on its highly 
organized molecular and structural composition (13). The secreted collagens 
displayed here similar fibrils organization and structure in all chondrogenic pellets, 
regardless of AA supplementation. Together with the similar hydroxylation profiles, 
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this suggested that the engineered extracellular matrix could have similar 
biomechanical features, even if produced in the absence of ascorbic acid (51). 
Altogether, the absence of AA was shown here to result in a very similar cartilaginous 
extracellular matrix, but with reduced quantities of collagens. On the other hand the 
omission or a temporarily discontinued supply of AA in chondrogenic medium could 
help in simplifying the automation of bioreactors, which will be required to drastically 
lower the manufacturing expenses. In order to promote the clinical translation of 
tissue engineering in the long-term, a delicate balance between sufficient product 
quality and acceptable cost-efficiency needs to be reached (4,7). Since the 
extracellular matrix of engineered cartilage grafts will anyway have to further mature 
and will be remodeled after implantation, where AA is available at physiologic 
concentrations, the omission of AA2P could be considered. 
CONCLUSION 
In this study we demonstrated that ascorbic acid is not essential for the synthesis of 
collagen type I and type II with hydroxylated proline residues. Moreover the pellet 
culture of human nasal chondrocytes with or without ascorbic acid 2-phosphate 
resulted in similar cell viability, gene expression, cartilaginous extracellular matrix 
production and collagen fibril organization. Overall, the collected data support the 
possibility of omitting ascorbic acid from chondrogenic medium in certain conditions. 
Together with the increased knowledge on ascorbic acid 2-phosphate stability in 
serum-containing and serum-free medium under different conditions, these results 
will help to define an efficient strategy for medium storage and ascorbic acid 
supplementation that ensures adequate quality of in vitro engineered cartilage grafts. 
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Conclusions 
Engineered tissue grafts have the potential to substantially contribute to the 
treatment of challenging cartilage and bone lesions. In order to accelerate their 
clinical translation, engineered products will have to prove a fast restoration with 
predictable clinical outcome. For this objective, increased quality and reproducibility 
will be required, which can be accomplished through an extended knowledge and 
improved control of the cell phenotype during all phases of tissue graft 
manufacturing. In the previous chapters, I demonstrated that the growth and 
differentiation of chondrocytes and BMSC can be modulated in order to better 
maintain and utilize their potential for cartilage and bone tissue engineering. 
The relationship between chondrocyte proliferation and concurrent phenotypic 
changes was poorly understood. In chapter I, cell division tracking of primary 
chondrocytes revealed that the progression of de-differentiation is strongly connected 
to cell doublings. The cell subpopulation with the highest proliferation rate exhibited 
the lowest re-differentiation capacity, whereas the highest chondrogenic potential 
was found here in cells that were slowly dividing. Since over time rapidly proliferating 
cells will overgrow all other subpopulations, this underlines the importance of only 
moderate expansion for clinical applications. An uncoupling of the link between 
proliferation and de-differentiation would open completely new perspectives for 
cartilage tissue engineering by allowing an extensive cell expansion while 
maintaining cell differentiation and chondrogenic potential. The existence of a slowly 
proliferating subpopulation with an intrinsically higher chondrogenic capacity will need 
to be verified for a much larger number of donors. A prospective selection of these 
cells with superior regenerative properties or an elimination of fast growing cells with 
lower chondrogenic potential could help in the generation of engineered cartilage 
grafts with a reproducibly higher quality. 
The bioreactor-based expansion of BMSC on 3D ceramic scaffolds were reported to 
lead to more extensive bone formation than culture on 2D polystyrene, but the 
influence of the multiple different culture parameters was unknown. In chapter II, the 
decoupling of the substrate dimensionality from the substrate material provided 
valuable insights into their individual roles during BMSC culture. In contrast to 2D 
polystyrene, a perfused 3D polystyrene scaffold was sufficient to maintain the in vivo 
osteogenic potential of BMSC over 3 weeks, which underlines the important effect of 
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a 3D environment on the cell phenotype. A ceramic scaffold further increased the 
preservation of osteogenic capacity, proving the impact of the substrate material. 
Moreover it was demonstrated that the preexistence of a 3D niche of extracellular 
matrix, in which the expanded cells were embedded, was not required for subsequent 
bone formation. The direct expansion of BMSC in a 3D ceramic construct offers thus 
the possibility to conserve bone formation potential and to streamline the 
manufacturing of large-scale bone grafts. Alternatively, BMSC expanded in 3D 
scaffolds could be extracted and administered as cell suspensions for osteogenic cell 
therapies. 
Macrophages have been reported to play an important role in healing processes by 
modulating tissue inflammation and repair, but their influence on the chondrogenic 
differentiation capacity of BMSC has not been established yet. In chapter III, 
macrophages with a tissue repair phenotype were demonstrated to have a chondro-
inductive effect on BMSC with increased collagen type II expression and GAG 
production, while pro-inflammatory macrophages did not influence chondrogenesis. 
The observed chondro-induction seemed to be due to the survival of BMSC with high 
chondrogenic capacity and to be mediated by short distance interactions between the 
two cell types. In vivo, the presence of tissue-repair macrophages did not influence 
tissue maturation. Altogether, the coculture with tissue-repair macrophages can 
become an attractive strategy for the sustained chondrogenic differentiation of BMSC 
in vitro. 
The small molecule ascorbic acid is involved in collagen synthesis and is therefore a 
standard supplement in chondrogenic differentiation medium. However the limited 
stability of ascorbic acid presents a considerable challenge to the automation of liquid 
handling for cartilage graft manufacturing. The effect of omitting ascorbic acid during 
chondrogenic differentiation, with special regard to collagen synthesis and 
hydroxylation, was thus investigated in chapter IV. Ascorbic acid was found not to be 
essential for the production of collagens type I and type II with hydroxylated proline 
residues. Since cell viability, gene expression, and glycosaminoglycan production 
were also similar, these results supported the possibility of omitting ascorbic acid in 
certain conditions. The increased knowledge on ascorbic acid requirements will help 
to define an efficient strategy for medium storage and ascorbic acid supplementation 
that facilitates automation, while ensuring the quality of in vitro engineered cartilage 
grafts. 
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In this thesis, I highlighted four different approaches to gain increased control over 
the growth and differentiation of chondrocytes and BMSC. To reach the ultimate goal 
of a sufficiently high quality of engineered tissues for clinical translation, a 
combination of different actions will be required to direct the cell phenotype 
throughout all phases of the manufacturing process. During cell isolation, 
subpopulations promoting or impairing the regenerative potential should already be 
separated. The increased differentiation potential can then be preserved during 
proliferation by uncoupling phenotypic changes from cell divisions, possibly through 
the provision of specific 3D scaffolds. After sufficient expansion, the deposition of 
extracellular matrix can be enhanced by the coculture with macrophages promoting 
survival and differentiation. Finally in order to achieve cost-effectiveness through the 
implementation of automation, manufacturing procedures can be simplified by the 
omission of certain factors or process steps without compromising product quality 
(Fig. 1). The increased graft quality achieved through the control of the cell 
phenotype will thereby result in mature tissues which will need to be further evaluated 
in clinical trials. 
 
Figure 1: Increased quality of engineered tissues can be achieved by integrating the 
approaches presented in this work into the tissue engineering paradigm in order to 
better control the cell phenotype during all stages of the manufacturing process.
Patient
Selection of subpopulations with 
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Future perspectives 
Besides the above mentioned combination of the different approaches to provide a 
better control over the phenotype of mesenchymal cells, this work can also serve as 
a starting point for future studies exploring the cellular mechanisms of growth and 
differentiation of chondrocytes and BMSC, but also of other cell types used for tissue 
repair. Indeed the achievement of high product quality during graft manufacturing 
through robust processes controlling cell proliferation and differentiation is a recurring 
theme in many tissue engineering applications (Martin et al., 2014). 
The cell division tracking method employed in chapter I has been extensively used to 
gain mechanistic insights in the field of immunology (Quah and Parish, 2012). In 
order to further study the coupling between proliferation and de-differentiation of 
chondrocytes, the technique could be combined with quantitative imaging. Pathways 
that could be involved in the described interplay include cell spreading, motility and 
adhesion, maybe through RhoA or CD90 (Barker et al., 2004; Beier and Loeser, 
2010; Mammoto et al., 2004). Since no distinctive profile of cell surface protein 
expression was detected here to select cells with an intrinsically higher potential, 
testing of additional markers like the previously described CD44 or CD49e could help 
in better defining or even prospectively isolating these cells (Dowthwaite et al., 2004; 
Grogan et al., 2007; Williams et al., 2010). Also the combination with S100, another 
marker reported to indicate cell potency, could give helpful insights (Diaz-Romero et 
al., 2014). A transcriptomic analysis would probably provide a better understanding of 
the mechanisms responsible for the maintenance of a higher chondrogenic potential 
of these cells. The increased knowledge could then again be used to design more 
robust cartilage manufacturing processes. Moreover other cell types such as BMSC 
could benefit from the same method of cell division tracking to distinguish 
subpopulations with possibly diverse differentiation potential (Bara et al., 2014; 
Tormin et al., 2009). 
Considering that the 3D expansion in perfused bioreactors used in chapter II is also 
known to be more robust across different donors (Papadimitropoulos et al., 2014), 
this process could become the method of choice for the expansion of BMSC with 
maintained progenitor properties. Such a system could as well be used for the 
establishment of an artificial bone marrow niche to study hematopoiesis in vitro (Di 
Maggio et al., 2011). The effect of the developing niche made from extracellular 
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matrix on the maintenance of BMSC functionality during expansion still needs to be 
explored. Furthermore the ceramic substrate was shown here to preserve the bone 
formation potential of BMSC, without priming the cells towards an osteogenic 
phenotype. A better understanding of the interactions between BMSC and ceramic 
substrates could thus lead to the development of new materials that have superior 
properties to maintain the cells’ progenitor potential. In addition the same technique 
of bridging the gap between 2D polystyrene and 3D materials by the use of a 3D 
polystyrene scaffold could be employed to analyze different aspects of substrate 
dimensionality on other cell types (Baker and Chen, 2012). 
The coculture with macrophages resulted in an enhanced chondrogenesis and cell 
survival of BMSC in chapter III. The presence of macrophages was not sufficient 
though to stabilize the chondrogenic phenotype. Nevertheless this coculture method 
could be used to improve the formation of a cartilaginous template for bone tissue 
engineering through an endochondral pathway (Scotti et al., 2010). Moreover these 
results indicate that the presence of macrophages could be beneficial for the culture 
and differentiation of other progenitor cell types for regenerative purposes (Brown et 
al., 2014). In view of a direct application of these results, the administration of 
compounds promoting the recruitment/polarization of anti-inflammatory and tissue-
repair macrophages should be tested in an orthotopic large animal model (Hoemann 
et al., 2010). Supposedly these macrophages could promote chondrogenesis and 
also keep cells alive in hostile environments such as after microfracture surgery or 
after implantation in an osteoarthritic joint site. 
Ascorbic acid was shown in chapter IV to be an unessential component of 
chondrogenic medium. The molecules acting as a substitute for ascorbic acid in the 
role of antioxidant and co-factors of proline hydroxylation deserve further 
investigation. In addition, this study showed how inefficient process steps can be 
scrutinized and replaced by a more innovative process design, such as in the case of 
changing from manual to automated medium exchange procedures. For a faster 
clinical translation, tissue engineering processes that are inherently robust by their 
design need to be obtained (Martin et al., 2014). Once a certain robustness and 
quality have been achieved, a balance then needs to be found between what is 
technically or biologically feasible and what is cost-efficient for the clinical translation 
of tissue engineered products (Butler et al., 2000; Wendt et al., 2009). 
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Ultimately, besides a deeper understanding of the biological processes during the 
production of engineered tissue and ongoing work in advancing the automation of 
manufacturing, future research efforts in tissue engineering will have to address the 
more fundamental mechanisms of regeneration and disease of the human body. In 
fact, little attention has been given to date to the recipient side where the graft 
environment is likely to play an important role and could even be instructed to 
promote regeneration (Tonnarelli et al., 2014). In this context, the function of 
macrophages during inflammation and regeneration deserves further investigation 
(Brown et al., 2014). Moreover, the target quality of tissue grafts in terms of 
biomechanical properties needs to be better defined, by evaluating which features 
are essential to overcome the disabling condition and to support regeneration (Butler 
et al., 2000). A continuous and even intensified collaboration between clinicians, 
biologists and engineers will be required to develop and validate these novel 
paradigms. In this way, tissue engineering can hold its promise of delivering the most 
advanced and efficacious treatments for the cure of challenging cartilage and bone 
lesions. 
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